breath
sampl
estim
l
air
per
minut
kohlmeier
woodland
mucosa
respiratori
system
therefor
direct
continu
contact
environ
highli
expos
microorgan
may
pathogen
respiratori
infect
among
lead
caus
acut
ill
mortal
worldwid
respons
nearli
million
death
annual
major
occur
infant
children
develop
countri
girard
et
al
main
virus
respons
acut
respiratori
infect
includ
respiratori
syncyti
viru
rsv
influenza
viru
human
parainfluenza
viru
hpiv
human
metapneumoviru
hmpv
human
rhinoviru
hrv
coronavirus
adenovirus
howev
despit
public
health
import
infect
licens
vaccin
current
avail
influenza
virus
protect
immun
respiratori
viru
infect
complex
interplay
system
mucos
respons
howev
immun
respons
gener
natur
infect
may
provid
complet
protect
reinfect
may
actual
contribut
pathogenesi
diseas
review
section
pathogenesi
immun
respons
respiratori
viru
infect
vaccineinduc
immun
respons
must
therefor
aim
protect
less
pathogen
induc
natur
addit
understand
rel
contribut
mucos
system
immun
protect
remain
incomplet
exampl
well
known
inactiv
vaccin
influenza
given
intramuscularli
im
protect
owe
induct
system
humor
immun
absenc
robust
mucos
immun
respons
current
guidelin
vaccin
licensur
requir
influenza
vaccin
induc
system
immun
respons
howev
also
evid
intranas
vaccin
protect
owe
induct
mucos
immun
despit
less
impress
system
immun
respons
review
section
respiratori
viru
vaccin
unfortun
standard
method
measur
mucos
immun
respons
lack
reliabl
correl
protect
vaccin
protect
mucos
immun
identifi
chapter
review
main
viral
pathogen
respiratori
tract
immun
respons
induc
current
vaccin
vaccin
develop
control
virus
infect
respiratori
tract
belong
variou
famili
vari
genom
composit
presenc
absenc
envelop
replic
cycl
major
respiratori
virus
respons
acut
respiratori
infect
belong
paramyxovirida
famili
includ
rsv
hpiv
hmpv
virus
infect
cell
line
respiratori
tract
first
attach
cell
interact
viral
envelop
glycoprotein
one
cellular
receptor
host
cell
plasma
membran
exampl
hpiv
envelop
protein
hn
bind
sialic
acid
residu
extend
host
cell
schomack
et
al
g
protein
rsv
hmpv
bind
glycosaminoglycan
gag
compris
long
chain
disaccharid
form
part
cellular
glycocalyx
feldman
et
al
rsv
hmpv
f
protein
also
known
bind
gag
find
indic
f
protein
virus
involv
attach
interact
cellular
protein
nucleolin
integrin
respect
tayyari
et
al
cseke
et
al
upon
bind
host
cell
f
protein
undergo
conform
chang
expos
hydrophob
fusion
peptid
respons
fusion
paramyxoviru
envelop
host
cell
plasma
membran
viral
fusion
genom
releas
cytoplasm
viral
gene
transcrib
viral
genom
replic
collin
crow
collin
melero
paramyxoviru
genom
compris
singlestrand
negativesens
nonseg
rna
viral
rna
vrna
must
first
transcrib
positivesens
messeng
rna
mrna
viral
protein
translat
host
cell
machineri
achiev
viral
rnadepend
rna
polymeras
larg
l
protein
packag
virion
enter
host
cell
upon
infect
l
protein
also
respons
genom
replic
positivesens
complementari
rna
crna
serv
intermedi
templat
product
vrna
essenti
cofactor
l
protein
phospho
p
protein
tether
polymeras
reach
base
vrna
also
bind
n
protein
encapsid
vrna
crna
also
evid
transcript
enhanc
protein
switch
transcript
replic
mediat
protein
collin
crow
collin
melero
transcrib
viral
structur
protein
assembl
newli
synthes
viral
genom
packag
virion
bud
plasma
membran
matrix
protein
line
inner
surfac
viral
envelop
may
play
role
bud
henderson
et
al
teng
collin
addit
hn
protein
hpiv
also
involv
bud
clear
sialic
acid
residu
plasma
membran
karron
collin
complet
replic
cycl
paramyxovirus
evolv
multipl
mechan
prevent
activ
cellular
defens
respons
infect
nonstructur
ns
protein
rsv
collin
crow
c
v
protein
hpiv
karron
collin
one
addit
protein
found
paramyxovirus
short
transmembran
glycoprotein
sh
anchor
envelop
share
structur
featur
viroporin
group
hydrophob
molecul
insert
membran
infect
cell
increas
permeabl
small
molecul
ion
gonzalez
carrasco
orthomyxovirida
famili
includ
influenza
virus
bind
termin
sialic
acidgalactos
linkag
hemagglutinin
ha
envelop
glycoprotein
orthomyxoviru
attach
host
cell
initi
receptormedi
endocytosi
endosom
acidif
proton
permit
enter
influenza
virion
via
ion
channel
acidif
result
conform
chang
ha
protein
reveal
fusion
peptid
initi
membran
fusion
viral
envelop
endosom
membran
review
pales
shaw
ha
synthes
precursor
cleav
activ
form
cellular
proteas
amino
acid
sequenc
cleavag
site
determin
type
proteas
abl
activ
ha
trypsinlik
proteas
requir
cleavag
viru
limit
tissu
tropism
respiratori
tract
human
gastrointestin
tract
bird
howev
presenc
multipl
basic
residu
cleavag
site
extend
rang
proteas
cleav
ha
result
dissemin
often
lethal
infect
poultri
wright
et
al
viru
envelop
fuse
endosom
influenza
genom
enter
cytoplasm
orthomyxoviru
genom
compris
seven
eight
segment
singlestrand
negativesens
rna
segment
encod
one
protein
segment
encapsid
nucleoprotein
np
form
panhandl
compris
end
polymeras
complex
attach
togeth
known
viral
ribonucleoprotein
complex
nucleu
orthomyxoviru
vrna
either
transcrib
mrna
replic
mean
positivesens
crna
intermedi
viral
mrna
molecul
exit
nucleu
translat
cytoplasm
host
cell
machineri
structur
protein
assembl
plasma
membran
newli
synthes
viral
genom
packag
virion
bud
pales
shaw
individu
segment
traffic
plasma
membran
packag
remain
activ
area
research
matrix
protein
line
virion
beneath
envelop
may
import
morpholog
viral
assembl
plasma
membran
addit
neuraminidas
na
protein
permit
bud
cleav
sialic
acid
residu
host
cell
plasma
membran
pales
shaw
complet
replic
cycl
influenza
virus
inhibit
interferon
ifn
product
signal
achiev
ns
protein
pales
shaw
section
adenovirus
genom
coronavirus
rhinovirus
compris
positivesens
singlestrand
rna
translat
host
cell
machineri
cytoplasm
kennedi
et
al
coronavirus
belong
coronavirida
famili
envelop
attach
host
epitheli
cell
spike
envelop
protein
blau
holm
fusion
occur
plasma
membran
endocytosi
genom
translat
polyprotein
posttransl
process
structur
protein
form
viral
particl
nonstructur
protein
aid
viral
genom
replic
lai
et
al
rhinovirus
belong
picornavirida
famili
envelop
instead
capsid
icosahedr
symmetri
compris
four
protein
review
greenberg
kennedi
et
al
major
rhinovirus
bind
intercellular
adhes
greve
et
al
bind
lead
conform
chang
capsid
creat
pore
genom
enter
cytoplasm
translat
replic
bella
rossmann
adenovirus
nonenvelop
possess
capsid
icosahedr
symmetri
corner
fiber
protrud
capsid
make
contact
host
cell
receptor
initi
receptormedi
endocytosi
acidif
endosom
result
conform
chang
capsid
lead
viral
uncoat
releas
doublestrand
dna
genom
cell
genom
transport
nucleu
transcrib
rna
altern
splice
monocistron
mrna
translat
host
cell
machineri
earli
gene
product
earli
gene
product
remodel
intracellular
environ
favor
viral
replic
respons
viral
replic
late
phase
viral
life
cycl
concern
product
structur
protein
suffici
quantiti
ensur
adequ
packag
newli
synthes
genom
maxim
product
progeni
virion
releas
cell
lysi
berk
respiratori
virus
infect
variou
part
respiratori
tract
caus
rang
ill
mild
upper
respiratori
tract
urt
infect
urti
complic
sinus
otiti
media
lower
respiratori
tract
lrt
infect
lrti
lead
bronchiol
pneumonia
possibl
postinfecti
respiratori
complic
sensit
asthma
major
public
health
impact
lrti
rsv
respons
major
case
infant
hmpv
hpiv
influenza
also
lead
lrti
hmpv
affect
infant
almost
young
afflict
rsv
wherea
influenza
often
diagnos
children
month
age
older
rsv
influenza
also
recogn
import
caus
lrti
elderli
cardiopulmonari
diseas
immunosuppress
schmidt
moreov
influenza
pandem
occur
irregular
unpredict
interv
widespread
morbid
mortal
econom
consequ
addit
although
case
sever
acut
respiratori
syndrom
sar
sinc
sever
novel
coronavirus
identifi
includ
viru
respons
middl
east
respiratori
syndrom
mer
zaki
et
al
given
clinic
signific
infect
fact
licens
vaccin
avail
influenza
virus
unmet
need
vaccin
human
natur
host
rsv
infect
occur
annual
epidem
winter
spring
month
temper
climat
raini
season
tropic
girard
et
al
viru
highli
contagi
children
infect
first
year
life
peak
sever
diseas
usual
occur
month
age
peak
incid
hospit
infant
collin
melero
reinfect
also
common
one
studi
among
children
infect
first
year
life
reinfect
second
year
third
year
life
glezen
et
al
moreov
reinfect
independ
antigen
chang
viru
impli
protect
immun
mount
infect
protect
subsequ
reinfect
collin
melero
note
attempt
induc
protect
immun
respons
vaccin
global
estim
million
case
lrti
caus
rsv
children
year
age
requir
hospit
martinez
et
al
unit
state
one
studi
estim
million
children
year
age
requir
medic
attent
year
owe
rsv
botosso
et
al
anoth
studi
estim
rsv
respons
hospit
per
year
girard
et
al
unit
kingdom
total
annual
incid
hospit
attribut
rsv
per
children
year
age
per
children
year
age
wari
half
hospit
rsv
occur
previous
healthi
fullterm
infant
children
experienc
sever
lrti
caus
rsv
increas
risk
wheez
asthma
later
life
girard
et
al
pediatr
mortal
rsv
unit
state
estim
per
per
year
infant
year
age
per
per
year
children
year
age
one
studi
cooney
et
al
anoth
us
studi
rsv
estim
respons
death
per
year
girard
et
al
howev
estim
rsvassoci
death
occur
develop
countri
possibl
limit
healthcar
resourc
martinez
et
al
healthi
adult
reinfect
rate
approxim
per
year
though
hospit
rare
morbid
mortal
pronounc
elderli
estim
rsv
caus
averag
death
annual
unit
state
occur
individu
year
age
cooney
et
al
addit
cost
care
patient
sever
lrti
rsv
sequela
substanti
girard
et
al
rsv
infect
induc
antibodi
two
main
antigen
f
g
envelop
glycoprotein
g
protein
variabl
protein
rsv
basi
separ
strain
two
antigen
group
b
moreov
site
posit
select
partial
coincid
epitop
recogn
antigprotein
monoclon
antibodi
mab
suggest
immunedriven
rsv
evolut
botosso
et
al
howev
antig
mab
neutral
infect
martinez
et
al
select
pressur
therefor
weak
favor
slow
coevolut
sever
rsv
lineag
multipl
genotyp
within
group
cocircul
within
season
shift
predomin
group
b
occur
cycl
wari
contrast
sequenc
f
gene
highli
conserv
among
rsv
isol
despit
identif
number
neutral
mab
protein
impart
select
pressur
mutat
collin
melero
impli
function
f
protein
confer
structur
restrict
may
limit
antigen
divers
human
parainfluenza
virus
also
common
caus
acut
respiratori
infect
children
seroposit
year
age
cooney
et
al
rsv
reinfect
common
schomack
et
al
four
serotyp
hpiv
hpiv
serotyp
associ
broad
spectrum
upper
lower
respiratori
symptom
howev
frequent
associ
croup
laryngotracheobronch
like
caus
bronchiol
pneumonia
lrti
resembl
diseas
caus
rsv
schomack
et
al
less
frequent
caus
clinic
signific
diseas
though
studi
found
hpivposit
sampl
daycar
set
fairchok
et
al
hpiv
lrti
major
caus
hospit
children
year
age
second
rsv
though
infect
usual
selflimit
rare
fatal
unless
individu
immunosuppress
sever
infect
may
longterm
effect
lung
function
remain
unclear
schomack
et
al
hmpv
belong
subfamili
rsv
two
major
group
b
four
minor
subgroup
identifi
base
sequenc
variabl
g
f
glycoprotein
kroll
weinberg
rsv
hpiv
year
age
children
infect
hmpv
reinfect
common
kroll
weinberg
viru
also
season
distribut
main
occurr
winter
spring
kahn
hmpv
typic
lead
flulik
symptom
otherwis
healthi
adult
respons
hospit
lrti
children
lead
sever
diseas
elderli
immunocompromis
host
papenburg
boivin
boivin
et
al
influenza
virus
divid
type
b
c
base
antigen
differ
np
gene
influenza
virus
clinic
signific
divid
subtyp
base
antigen
differ
ha
na
gene
date
ha
na
subtyp
identifi
waterfowl
pales
shaw
subtyp
ha
identifi
bat
guatemala
peru
tong
et
al
tong
et
al
influenza
virus
caus
spectrum
clinic
ill
associ
infect
upper
lower
respiratori
tract
sever
diseas
associ
lrti
virus
spread
respiratori
droplet
direct
contact
annual
influenza
epidem
season
distribut
main
occurr
winter
month
season
influenza
temper
climat
girard
et
al
howev
unlik
rsv
hpiv
hmpv
influenza
virus
broad
host
rang
includ
bird
pig
dog
hors
marin
mammal
human
main
reservoir
infect
aquat
bird
pales
shaw
wright
et
al
broad
host
rang
togeth
segment
natur
influenza
viru
genom
make
epidemiolog
influenza
complex
give
rise
zoonot
infect
pandem
pandem
influenza
aris
novel
viru
emerg
readili
transmit
person
person
major
popul
suscept
infect
avian
anim
viru
cross
speci
barrier
circul
human
popul
probabl
immunolog
therefor
suscept
infect
howev
viru
must
abl
transmit
effici
person
person
pandem
occur
influenza
viru
genom
segment
host
infect
two
influenza
virus
potenti
exist
gene
segment
reassort
progeni
viru
contain
gene
parent
viru
produc
wright
et
al
viru
circul
within
human
popul
reassort
one
novel
human
result
viru
may
possess
gene
allow
replic
effici
human
glycoprotein
popul
immunolog
pandem
could
occur
introduct
viru
novel
ha
subtyp
human
popul
known
antigen
shift
wright
et
al
three
global
influenza
pandem
record
twentieth
centuri
virus
subtyp
respect
anoth
pandem
influenza
viru
emerg
mexico
girard
et
al
viru
antigen
unrel
previous
circul
season
virus
molecular
studi
reveal
reassort
gene
deriv
virus
circul
pig
north
american
triplereassort
classic
swine
eurasian
avianlik
swine
virus
countri
median
age
infect
pandem
estim
year
individu
infect
led
mild
selflimit
urti
howev
confirm
case
unit
state
canada
requir
hospit
casefat
rate
moreov
nearli
onethird
fatal
among
hospit
patient
occur
previous
healthi
individu
girard
et
al
pandem
newli
emerg
subtyp
becam
establish
caus
annual
season
influenza
epidem
unit
state
estim
million
case
influenza
occur
annual
approxim
requir
hospit
lambert
fauci
current
vaccin
aim
circul
subtyp
influenza
predomin
circul
strain
influenza
b
therefor
trival
vaccin
howev
two
antigen
distinct
lineag
influenza
b
virus
victoria
yamagata
cocircul
world
health
organ
recommend
influenza
vaccin
contain
lineag
clinic
trial
quadrival
vaccin
contain
influenza
virus
victoria
yamagata
influenza
b
virus
conduct
use
unit
state
receiv
interim
recommend
advisori
committe
immun
practic
influenza
season
dolin
owe
low
fidel
rnadepend
rna
polymeras
influenza
immun
select
pressur
ha
protein
viral
replic
yield
quasispeci
may
differ
antigen
parent
viru
therefor
season
predomin
circul
strain
may
antigen
distinct
previou
year
phenomenon
known
antigen
drift
lead
need
updat
influenza
vaccin
annual
wright
et
al
sporad
infect
subtyp
influenza
report
human
close
direct
contact
infect
anim
addit
variant
virus
infect
human
major
close
contact
pig
epperson
et
al
far
limit
transmiss
virus
peopl
though
concern
may
acquir
mutat
gene
segment
allow
effici
spread
person
person
coronavirus
frequent
caus
common
cold
caus
urti
throughout
world
age
group
lead
million
day
work
school
absenc
physician
visit
frequent
inappropri
antibiot
use
greenberg
coronavirus
transmit
respiratori
droplet
report
caus
common
cold
peak
preval
late
fall
winter
earli
spring
first
human
coronavirus
hcov
recogn
signific
respiratori
pathogen
identifi
greenberg
wherea
infect
major
coronavirus
associ
selflimit
urt
symptom
otherwis
healthi
individu
coronaviru
identifi
agent
respons
sar
drosten
et
al
ksiazek
et
al
sar
coronaviru
sarscov
emerg
guangdong
provinc
china
novemb
spread
countri
lead
case
death
worldwid
time
outbreak
brought
control
june
subsequ
heighten
intern
surveil
coronavirus
led
identif
strain
nh
greenberg
previous
hrv
classifi
two
speci
hrva
contain
serotyp
hrvb
contain
serotyp
novel
speci
hrvc
identifi
contain
least
serotyp
jacob
et
al
hrv
spread
direct
contact
handtohand
contact
aerosol
tradit
associ
urti
caus
common
cold
makela
et
al
howev
increasingli
recogn
caus
lrti
particularli
patient
asthma
infant
elderli
immunocompromis
individu
jacob
et
al
bronchiol
common
clinic
manifest
hospit
children
infect
hrv
hrv
also
common
pathogen
viral
communityacquir
pneumonia
hrv
also
associ
exacerb
asthma
chronic
obstruct
pulmonari
diseas
jacob
et
al
write
serotyp
seven
speci
adenoviru
identifi
tissu
tropism
clinic
manifest
vari
serotyp
virus
respons
febril
respiratori
diseas
gastrointestin
ill
review
lynch
et
al
adenovirus
estim
respons
pediatr
adult
respiratori
tract
infect
ison
lee
et
al
spread
primarili
via
respiratori
droplet
direct
contact
fomit
case
children
year
age
lynch
et
al
howev
epidem
also
describ
children
adult
especi
militari
recruit
close
crowd
set
individu
develop
selflimit
urt
infect
may
asymptomat
conjunct
tonsil
otiti
media
croup
occur
infect
also
spread
caus
bronchiol
pneumonia
dissemin
caus
viral
mening
enceph
fatal
lynch
et
al
mani
factor
determin
pathogenesi
diseas
clinic
outcom
includ
factor
pertain
viru
host
genet
host
immun
respons
environ
site
viral
replic
may
influenc
pathogenesi
diseas
outcom
infect
exampl
season
influenza
virus
usual
infect
epithelium
urt
consist
common
clinic
manifest
season
influenza
wherea
highli
pathogen
avian
influenza
virus
subtyp
show
stronger
tropism
lrt
urt
kuiken
et
al
virus
attach
abundantli
clara
club
cell
line
bronchiol
type
ii
pneumocyt
line
alveoli
alveolar
macrophag
alveoli
consist
clinic
manifest
diffus
alveolar
damag
kuiken
et
al
rsv
also
target
type
alveolar
nonbasilar
epitheli
cell
possibl
alveolar
macrophag
may
contribut
lrti
van
drunen
littelvan
den
hurk
watkiss
tissu
tropism
determin
part
receptor
prefer
viru
exampl
cell
line
urt
human
predominantli
possess
sialic
acid
residu
termin
linkag
galactos
wherea
cell
line
human
lrt
linkag
shinya
et
al
believ
abil
influenza
viru
ha
preferenti
bind
sialosaccharid
therefor
partli
determin
tissu
tropism
henc
clinic
outcom
host
cell
infect
type
ifn
proinflammatori
cytokin
express
cellular
translat
suppress
antivir
state
induc
discuss
section
immun
respons
respiratori
viru
infect
howev
virus
infect
respiratori
tract
modul
host
respons
infect
block
ifn
activ
andor
signal
inhibit
apoptosi
prevent
host
effect
clear
viral
infect
cell
induc
antivir
state
neighbor
cell
therebi
promot
viral
replic
infect
tissu
may
contribut
observ
patholog
rsv
effect
paramyxoviru
subvert
host
cell
respons
inhibit
apoptosi
type
ifn
product
signal
mean
protein
inhibit
nuclear
activ
bind
sequestr
cellular
protein
kinas
r
pkr
viral
n
protein
inhibit
product
stress
granul
restrict
viral
replic
collin
melero
influenza
virus
encod
protein
downregul
ifn
product
pales
shaw
hpiv
encod
either
c
protein
v
protein
suppress
ifn
induct
signal
karron
collin
wherea
sarscov
encod
eight
protein
antagon
ifn
respons
varieti
mechan
totura
baric
addit
block
ifn
activ
signal
virus
employ
mean
ensur
replic
face
host
immun
rsv
g
protein
highli
glycosyl
featur
may
inhibit
bind
antibodi
protein
highli
variabl
enabl
substanti
popul
immuneescap
mutant
produc
infect
addit
truncat
solubl
form
g
protein
produc
infect
act
decoy
antigen
bind
rsvspecif
antibodi
thu
reduc
avail
neutral
viru
rsv
also
infect
antigenpres
cell
apc
dendrit
cell
dc
affect
matur
antigenpresent
function
lead
dysregul
adapt
immun
respons
van
drunen
littelvan
den
hurk
watkiss
number
virul
determin
also
identifi
influenza
virus
includ
ha
polymeras
complex
exampl
presenc
multibas
site
ha
gene
render
virus
highli
pathogen
poultri
abl
replic
system
bosch
et
al
kawaoka
webster
addit
substitut
glutam
acid
e
residu
lysin
k
residu
amino
acid
posit
protein
polymeras
associ
alter
host
rang
subbarao
et
al
virul
human
mice
experiment
infect
avian
virus
hatta
et
al
munster
et
al
subbarao
et
al
absenc
mutat
mutat
also
correl
increas
virul
li
et
al
absenc
mutat
found
contribut
influenza
viru
replic
virul
mehl
doudna
addit
mutat
protein
shown
contribut
virul
pandem
virus
conenello
et
al
sever
virul
determin
identifi
protein
includ
review
kuiken
et
al
sever
host
factor
known
contribut
sever
respiratori
viru
diseas
outcom
infect
exampl
known
sever
rsv
lrti
infant
associ
prematur
chronic
lung
diseas
congenit
heart
diseas
cell
immunodefici
risk
factor
includ
low
birth
weight
multipl
birth
male
gender
low
titer
matern
deriv
antirsv
antibodi
groothui
et
al
van
drunen
littelvan
den
hurk
watkiss
addit
low
level
vitamin
cordblood
healthi
neonat
correl
increas
risk
rsv
lrti
first
year
life
belderbo
et
al
infant
also
greater
risk
lrt
diseas
hpiv
infect
older
children
attribut
smaller
airway
suscept
obstruct
immatur
immun
respons
presenc
antihpiv
matern
antibodi
suppress
primari
antibodi
respons
crow
william
karron
collin
adult
immunodefici
immunosuppress
old
age
may
lead
sever
ill
collin
melero
addit
number
genet
polymorph
also
describ
host
gene
may
affect
outcom
respiratori
viru
infect
diseas
sever
singlenucleotid
polymorph
identifi
gene
encod
surfact
protein
surfact
protein
b
c
pattern
recognit
receptor
prr
tolllik
receptor
tlr
chemokin
cytokin
rant
chemokin
cytokin
receptor
adhes
molecul
eselectin
hla
molecul
hlaa
b
among
other
miyairi
devincenzo
poland
et
al
howev
consist
result
obtain
studi
probabl
result
differ
studi
design
sampl
size
etc
addit
true
variabl
clearli
contribut
genet
polymorph
diseas
outcom
complex
remain
activ
area
research
well
respons
viral
clearanc
protect
reinfect
host
innat
adapt
immun
respons
respiratori
virus
lead
patholog
enhanc
diseas
especi
import
bear
mind
vaccin
develop
vaccineinduc
immun
respons
must
protect
infect
without
lead
immunopatholog
excess
inflamm
import
compon
pathogenesi
respiratori
viru
infect
upregul
lead
recruit
neutrophil
site
infect
although
cell
may
particip
viru
elimin
high
number
also
caus
patholog
upregul
known
correl
rsv
diseas
sever
goetghebu
et
al
influenza
infect
overproduct
cytokin
type
ii
ifn
chemokin
also
result
recruit
immun
cell
site
infect
result
damag
lung
tissu
cheung
et
al
de
jong
et
al
elev
also
describ
children
hpiv
diseas
associ
sever
hpiv
diseas
high
concentr
review
schomack
et
al
addit
rsv
solubl
g
protein
lead
leukocyt
recruit
mimick
chemokin
fractalkin
tripp
et
al
exacerb
inflamm
pathogenesi
also
enhanc
insuffici
antiinflammatori
immun
respons
lung
cytokin
carlson
et
al
leboud
et
al
sun
et
al
insuffici
number
immunosuppress
resid
alveolar
macrophag
rygiel
et
al
snelgrov
et
al
dysregul
adapt
immun
respons
also
lead
increas
patholog
cellular
immun
respons
implic
immunopathogenesi
rsv
diseas
van
drunen
littelvan
den
hurk
et
al
variou
defens
mechan
evolv
respiratori
tract
prevent
control
infect
current
consider
effort
develop
improv
vaccin
respiratori
virus
howev
achiev
goal
complic
incomplet
knowledg
immun
system
recogn
contain
elimin
respiratori
virus
section
discuss
immun
respons
respiratori
viru
infect
initi
innat
adapt
respons
follow
primari
viru
infect
recal
immun
respons
secondari
infect
addit
advanc
understand
respiratori
mucos
immun
discuss
common
featur
respiratori
viru
infect
initi
infect
establish
epitheli
cell
line
respiratori
tract
epitheli
cell
well
alveolar
macrophag
dc
expos
content
airway
lumen
detect
presenc
invad
viru
prr
holt
et
al
recognit
pathogenassoci
molecular
pattern
pamp
receptor
initi
cascad
signal
result
product
cytokin
chemokin
releas
inflammatori
mediat
surround
environ
establish
local
antivir
state
addit
chemokin
provid
necessari
signal
recruit
leukocyt
site
infect
final
combin
inflammatori
cytokin
prr
initi
process
dc
matur
traffick
requir
induct
adapt
immun
respons
holt
et
al
best
describ
prr
tlr
famili
respect
respiratori
virus
recogn
variou
product
viral
replic
doublestrand
rna
singlestrand
rna
unmethyl
cpg
dna
respect
alexopoul
et
al
diebold
et
al
hagglund
et
al
lund
et
al
recogn
f
protein
rsv
kurt
jone
et
al
tlr
recogn
nucleic
acid
locat
late
endosom
locat
optim
abil
tlr
interact
viral
nucleic
acid
limit
access
hostderiv
nucleic
acid
heil
et
al
matsumoto
et
al
although
tlr
express
cell
surfac
within
cell
util
differ
signal
pathway
receptor
activ
transcript
ifninduc
gene
viral
rna
also
recogn
cytoplasm
sensor
rna
helicas
retino
acidinduc
gene
protein
interact
rna
import
earli
cytokin
product
respons
numer
rna
virus
hornung
et
al
pichlmair
et
al
yoneyama
et
al
kato
et
al
pothlichet
et
al
graham
et
al
melanoma
differentiationassoci
gene
protein
relat
helicas
recogn
polyinosin
polycytidyl
acid
crucial
innat
recognit
picornavirus
human
metapneumoviru
infect
banoslara
mdel
et
al
similar
signal
tlr
pathway
util
rna
helicas
ultim
trigger
ifnregulatori
factor
activ
le
goffic
et
al
key
differ
molecul
tlr
rna
helicas
local
throughout
cytosol
rather
restrict
intracellular
compart
thu
pathogen
paramyxovirus
enter
endosom
trigger
innat
immun
respons
via
rna
helicas
innat
recognit
viral
compon
prr
describ
lead
program
gene
express
promot
local
antivir
state
elicit
recruit
inflammatori
cell
site
infect
type
interferon
includ
commonli
associ
earli
antivir
respons
lung
numer
studi
mice
human
shown
plasmacytoid
dc
pdc
primari
sourc
cytokin
infect
virus
asselinpaturel
et
al
mcgill
et
al
howev
level
redund
respect
ifn
product
alveolar
macrophag
pdc
predomin
depend
type
viral
infect
pribul
et
al
precis
contribut
pdc
lung
antivir
immun
also
controversi
sever
vitro
studi
show
respiratori
virus
includ
influenza
virus
infect
pdc
pdc
activ
virusspecif
cell
wikstrom
stumbl
geurtsvankessel
lambrecht
evid
major
role
pdc
control
influenza
viru
vivo
absent
type
ifn
produc
respiratori
viru
infect
act
concert
prr
signal
form
feedback
loop
signal
receptor
promot
sustain
product
proinflammatori
cytokin
lungresid
innat
immun
cell
chan
et
al
nakajima
et
al
almansa
et
al
proinflammatori
cytokin
prrmediat
signal
also
prompt
alveolar
macrophag
dc
epitheli
cell
initi
coordin
program
chemokin
product
viral
infect
exampl
dc
secret
success
wave
chemokin
influenza
viru
infect
begin
capabl
recruit
inflammatori
cell
neutrophil
natur
killer
nk
cell
lung
follow
chemokin
associ
recruit
monocyt
cell
piquera
et
al
maroi
et
al
teijaro
et
al
cytokin
activ
monocyt
macrophag
neutrophil
drive
develop
cell
adapt
respons
mice
human
cell
differenti
presenc
result
effector
cell
respect
chung
et
al
dinarello
lasigli
et
al
ohno
et
al
cytokin
process
result
activ
activ
regul
inflammasom
larg
mutimer
structur
martinon
et
al
subgroup
nucleotidebind
domain
leucinerich
repeatcontain
protein
nlrp
key
mediat
inflammasom
activ
inflammasom
divid
two
categori
activ
driven
hostand
environmentderiv
molecul
activ
driven
pathogenassoci
activ
includ
pamp
deriv
bacteria
viru
fungu
protozoa
paramyxovirus
rsv
orthomyxovirus
influenza
virus
activ
inflammasom
kanneganti
et
al
segovia
et
al
komun
et
al
shown
play
critic
antivir
role
influenza
virusinfect
mice
thoma
et
al
ichinoh
et
al
allen
et
al
infect
lrt
antigenbear
matur
dc
enter
lymph
node
drain
lung
form
stabl
interact
cell
specif
antigen
cell
receptor
tcr
signal
deliv
antigen
recognit
addit
accessori
signal
deliv
costimulatori
molecul
result
cell
prime
clonal
expans
antigenspecif
effector
cell
moon
et
al
obar
et
al
instruct
deliv
dc
initi
expans
phase
dramat
impact
surviv
function
respond
cell
instanc
express
fasl
dc
influenza
infect
shown
regul
magnitud
cell
respons
legg
bracial
resid
convent
dc
mediastin
lymph
node
also
mediat
induct
protect
immun
influenza
viru
cell
found
crosspres
viral
antigen
cell
without
directli
infect
viru
belz
et
al
activ
clonal
expans
antigenspecif
effector
cell
drain
lymph
node
cell
lose
prefer
lymphoid
tissu
migrat
via
bloodstream
site
infect
antivir
mechan
describ
exert
analysi
chemokin
express
lung
adapt
phase
immun
respons
shown
elev
express
numer
molecul
associ
effector
cell
traffick
monick
et
al
instanc
traffick
effector
cell
rsv
infect
partial
depend
chemokin
receptor
may
play
role
paramyxoviru
infect
harcourt
et
al
appear
antigenspecif
effector
cell
site
viru
infect
first
observ
around
day
infect
influenza
parainfluenza
virus
mice
pommerenk
et
al
kohlmeier
woodland
lawrenc
bracial
roman
et
al
continu
migrat
effector
cell
lymphoid
tissu
acut
infect
result
massiv
increas
number
antigenspecif
cell
lung
airway
parenchyma
day
influenza
viru
infect
flynn
et
al
arriv
effector
cell
immedi
dramat
impact
viral
load
kohlmeier
et
al
adapt
immun
respons
induc
respiratori
viru
infect
shown
figur
upon
arriv
effector
site
figur
antigenspecif
cell
first
interact
apc
dc
shen
et
al
moreov
subset
dc
class
hi
present
crucial
cell
surviv
factor
antivir
cell
tran
mcgill
et
al
immun
respons
determin
cytokin
milieu
respiratori
tract
well
type
level
costimulatori
molecul
express
apc
instanc
lung
dc
bias
promot
respons
like
via
product
absenc
cytokin
product
leukotrien
dodg
et
al
barrett
et
al
effector
cell
employ
one
follow
three
antivir
mechan
figur
first
cell
promot
lysi
infect
cell
exocytosi
granul
contain
perforin
granzym
trapani
smyth
hou
doherti
second
cell
induc
apoptosi
infect
cell
express
fa
ligand
fasl
hou
doherti
tnfrelat
apoptosisinduc
ligand
trail
brinck
et
al
third
cell
produc
proinflammatori
regulatori
mediat
encount
viral
infect
cell
hamada
et
al
sever
studi
suggest
crucial
role
cytolyt
function
effector
cell
influenza
viru
infect
direct
lysi
infect
cell
requir
tcrmediat
recognit
process
viral
antigen
infect
target
cell
brinck
et
al
topham
doherti
contrast
releas
proinflammatori
mediat
cell
modest
impact
viru
clearanc
recoveri
also
evid
model
influenza
infect
infect
alveolar
epitheli
cell
may
elimin
host
respons
action
macrophag
capabl
trigger
apoptosi
traildepend
mechan
herold
et
al
effector
cell
also
found
exhibit
cytotox
activ
vitro
contribut
mechan
viru
clearanc
vivo
modest
agrewala
et
al
graham
et
al
restrict
cytolysi
cell
bear
viral
antigen
present
major
histocompat
complex
mhc
class
ii
molecul
cell
includ
mononuclear
phagocyt
cell
lung
parenchym
cell
type
ii
alveolar
epitheli
cell
express
mhc
class
ii
molecul
either
constitut
induc
manner
debbabi
et
al
primari
role
antivir
cell
support
activ
differenti
b
cell
lead
antibodi
product
topham
et
al
topham
doherti
discuss
anoth
aspect
effector
cell
potenti
exert
cytotox
activ
simultan
produc
cytokin
exampl
influenza
infect
interact
prime
cell
lung
dc
elicit
cytokin
product
cytotox
phenotyp
hufford
et
al
summar
cellular
immun
respons
primari
influenza
infect
specif
effector
cell
lung
predominantli
produc
figur
upon
viru
infect
viral
antigen
die
respiratori
epitheli
cell
transport
lung
lymph
node
migratori
antigenpres
cell
mous
dendrit
cell
dc
human
monocytederiv
dc
stimul
cell
respons
viral
antigen
also
transfer
lymph
noderesid
dc
present
cell
addit
plasmacytoid
dendrit
cell
pdc
earli
sourc
antivir
type
interferon
via
recognit
viral
rna
effector
cell
also
produc
card
et
al
pipel
et
al
mayer
et
al
effector
cell
local
respiratori
epithelium
induc
apoptosi
infect
epitheli
cell
fasfasl
interact
exocytosi
cytolyt
granul
contain
perforin
granzym
tripp
et
al
b
cell
found
interspers
lung
interstitium
cervic
mediastinalbronchi
lymph
node
drain
upper
lower
respiratori
tract
respect
respiratori
viru
infect
tertiari
lymphoid
structur
also
form
along
branch
point
bronchial
tree
call
bronchusassoci
lymphoid
tissu
balt
brandtzaeg
balt
contain
organ
b
cell
area
germin
center
antibodyform
cell
randal
b
cell
respons
classifi
three
categori
innatelik
b
cell
respons
tdepend
b
cell
respons
tindepend
b
cell
respons
innatelik
b
cell
respons
consist
antibodi
produc
almost
exclus
cell
small
subset
b
cell
character
uniqu
development
origin
phenotyp
tissu
distribut
regul
compar
convent
b
cell
baumgarth
et
al
baumgarth
tdepend
b
cell
respons
b
cell
respons
facilit
cell
wherea
tindepend
b
cell
respons
shown
cell
defici
result
drastic
reduc
humor
respons
influenza
viru
infect
mice
mozdzanowska
et
al
howev
mice
lack
cell
still
protect
lethal
infect
mozdzanowska
et
al
highlight
import
tindepend
b
cell
respons
b
cell
respons
critic
viral
clearanc
primari
respiratori
viru
infect
influenza
gerhard
although
control
earli
infect
day
postinfect
impair
bcelldefici
mice
mice
fail
clear
viru
ultim
succumb
infect
graham
bracial
lee
et
al
studi
influenza
virusinfect
mice
also
show
serum
antibodi
titer
first
detect
around
day
postinfect
least
day
later
respons
detect
respiratori
tract
steadili
increas
month
rel
high
figur
effector
phase
respons
influenzaspecif
cell
elicit
cytotox
respons
nitric
oxid
produc
subset
dc
neutrophil
contribut
viral
clearanc
immunopatholog
lung
hi
dc
present
crucial
cell
surviv
factor
antivir
cell
tran
promot
product
chemokin
drain
lymph
node
dc
contribut
expans
specif
cell
convent
dc
cdc
induc
respons
plasmablast
initi
produc
igm
effector
cell
provid
help
virusspecif
b
cellplasmablast
differenti
prolifer
pdc
also
play
detriment
role
elimin
virusspecif
cell
process
involv
fasl
antibodi
titer
maintain
life
virusspecif
antibodyform
cell
resid
transient
spleen
around
day
postinfect
persist
long
term
bone
marrow
jone
ada
hyland
et
al
recoveri
infect
figur
state
immunolog
memori
ensu
individu
better
abl
control
subsequ
infect
pathogen
ahm
gray
immunolog
memori
maintain
b
cell
subset
profound
differ
gener
traffick
mainten
b
cell
memori
antigenspecif
memori
cell
persist
increas
frequenc
reduc
requir
costimulatori
signal
comparison
cell
respond
quickli
antigen
restimul
woodland
et
al
case
influenza
parainfluenza
piv
viru
infect
clearli
establish
memori
cell
subset
respond
control
secondari
infect
woodland
dutton
b
cell
memori
character
two
distinct
popul
longliv
plasma
cell
continu
secret
antibodi
memori
b
cell
persist
quiescent
state
bachmann
et
al
slifka
ahm
gener
longliv
plasma
cell
depend
cognat
tb
cell
interact
signal
occur
germin
center
noell
et
al
lee
et
al
antigenspecif
igg
iga
antibodi
maintain
long
infect
may
protect
heterolog
strain
viru
exampl
peopl
born
finland
preexist
antibodi
influenza
viru
probabl
relationship
pandem
influenza
viru
circul
first
part
twentieth
centuri
ikonen
et
al
yu
et
al
presenc
crossreact
antibodi
contribut
unexpectedli
low
number
elderli
sever
ill
pandem
compar
season
influenza
viru
strain
monsalvo
et
al
odonnel
et
al
although
neutral
antibodi
direct
ha
globular
head
highli
effici
prevent
clear
influenza
viru
infect
also
figur
memori
phase
migratori
lung
dc
captur
viral
antigen
retain
follicular
dc
fdc
tertiari
lymphoid
organ
present
specif
cell
respiratori
drain
lymph
node
stimul
cell
upregul
express
caus
retain
lymph
node
drain
site
primari
infect
resid
dc
abl
reactiv
memori
respons
lymph
node
lung
dc
promot
product
iga
process
depend
gener
b
cell
memori
particularli
gener
longliv
plasma
cell
depend
cognat
tb
cell
interact
signal
occur
germin
center
provid
select
pressur
viral
immun
evas
crossprotect
variou
influenza
subtyp
term
heterosubtyp
immun
requir
immun
system
recogn
epitop
conserv
subtyp
epitop
found
membraneproxim
stalk
region
ha
han
marasco
intern
protein
nucleoprotein
protein
antistalk
antibodi
inhibit
virion
bind
mammalian
host
cell
inhibit
fusion
viral
envelop
endosom
membran
broadli
neutral
activ
passiv
protect
mice
lethal
challeng
vivo
okuno
et
al
throsbi
et
al
sui
et
al
interestingli
crossreact
antiha
stalk
monoclon
antibodi
gener
acut
respons
pandem
viru
also
healthi
subject
vaccin
inactiv
viru
corti
et
al
sui
et
al
wrammert
et
al
induc
hightit
antiha
stalk
antibodi
human
remain
activ
area
univers
influenza
vaccin
research
cellular
immun
respons
crossreact
epitop
often
express
intern
viral
protein
also
provid
substanti
degre
protect
serolog
distinct
virus
yewdel
et
al
rimmelzwaan
osterhau
although
heterosubtyp
cellular
respons
abl
prevent
reinfect
amelior
diseas
reduc
maxim
viral
load
mediat
faster
viral
clearanc
provid
substanti
degre
protect
challeng
lethal
dose
viru
anim
model
hillair
et
al
also
epidemiolog
evid
heterosubtyp
cellular
immun
play
role
respons
infect
novel
influenza
virus
human
howev
protect
effect
appear
weak
may
wane
time
epstein
epstein
price
therefor
suggest
protect
cellular
immun
could
sustain
reinfect
annual
immun
effector
mechan
heterosubtyp
immun
remain
ambigu
murin
model
influenza
viru
infect
heterosubtyp
immun
observ
absenc
antibodi
recogn
influenza
envelop
glycoprotein
thought
mediat
primarili
cell
rel
small
contribut
cell
mckinstri
et
al
heterotyp
influenzaspecif
cell
also
shown
lyse
influenza
virusinfect
cell
nguyen
et
al
howev
heterosubtyp
immun
observ
tcelldefici
mice
mice
lack
b
cell
indic
redund
system
investig
found
heterosubtyp
immun
requir
nguyen
et
al
requir
properli
diversifi
antibodi
repertoir
nguyen
et
al
mucos
immun
system
describ
detail
elsewher
book
howev
featur
uniqu
respiratori
tract
worth
note
like
immun
system
gener
mucos
immun
system
respiratori
tract
use
innat
specif
mechan
prevent
limit
infect
innat
defens
includ
physic
chemic
factor
secret
mucu
trap
microorgan
antigen
facilit
transport
bodi
mucociliari
motion
mucos
secret
also
contain
chemic
activ
substanc
includ
acid
lactoferrin
lysozym
inhibit
growth
microb
addit
lumin
side
respiratori
tract
physic
protect
layer
epitheli
cell
adher
tight
junction
use
occludin
variou
member
claudin
famili
adher
junction
use
ecadherin
tsukita
et
al
human
respiratori
tract
divid
anatom
urt
compris
nose
mouth
pharynx
lrt
includ
trachea
bronchi
lung
lymphoid
tissu
waldey
ring
repres
line
demarc
unpair
nasopharyng
tonsil
also
call
adenoid
palatin
lingual
tonsil
constitut
waldey
ring
tubal
tonsil
later
pharyng
band
less
promin
compon
dolen
et
al
lymphoid
tissu
function
compar
nasal
noseassoci
lymphoid
tissu
nalt
rodent
compos
two
pair
lymphoepitheli
structur
besid
nasopharyng
duct
dorsal
cartilagin
soft
palat
kuper
et
al
fukuyama
et
al
howev
rodent
tonsil
waldey
ring
strateg
situat
nalt
gener
mucos
immun
element
expos
airborn
alimentari
antigen
addit
human
tonsil
deep
antigenretain
crypt
tonsil
express
germin
center
shortli
birth
wherea
rodent
nalt
plain
surfac
requir
extern
stimulu
induc
express
germin
center
brandtzaeg
tissu
equival
waldey
ring
also
found
nonhuman
primat
loo
chin
harkema
et
al
hors
mair
et
al
mair
et
al
function
studi
perform
speci
mucosaassoci
lymphoid
tissu
malt
includ
nalt
balt
consist
follicleassoci
epithelium
tcelland
bcellenrich
area
initi
antigenspecif
immun
respons
occur
special
gateway
compris
microfold
cell
locat
epithelium
overli
malt
follicl
cilia
apic
side
cell
shorter
convent
epitheli
cell
basal
side
larg
pocketlik
structur
hold
immunocompet
cell
requir
gener
immun
respons
cell
b
cell
apc
lysosom
develop
cell
poor
case
antigen
pass
cell
unmodifi
taken
dc
pocket
sato
kiyono
upon
encount
antigen
dc
migrat
cell
region
malt
present
peptid
antigen
via
mhc
molecul
cell
antigenspecif
cell
becom
prime
clonal
expand
leav
follicl
enter
circul
home
effector
site
elicit
mechan
involv
viral
clearanc
describ
b
cell
region
germin
center
form
antibodi
class
switch
occur
cerutti
class
switch
iga
predominantli
occur
malt
owe
action
igaassoci
cytokin
famili
mcghee
et
al
mestecki
mcghee
cerutti
postswitch
iga
b
cell
leav
malt
effer
lymph
vessel
control
lipid
mediat
cell
enter
circulatori
system
gohda
et
al
lazaru
et
al
home
effector
site
found
unorgan
lymphat
tissu
spread
lamina
propria
underli
mucos
epithelium
lamina
propria
b
cell
differenti
plasma
cell
secret
iga
igd
igm
igg
antibodi
although
iga
major
mucos
antibodi
isotyp
shikina
et
al
shimoda
et
al
surgic
remov
murin
nalt
cervic
lymph
node
howev
abrog
cellular
antibodi
immun
respons
experiment
influenza
infect
suggest
may
addit
induct
site
nalt
demonstr
dissect
rel
contribut
antiinfluenza
immun
difficult
urt
iga
major
mediat
immun
influenza
mice
recov
influenza
infect
immun
reinfect
abrog
intranas
instil
antiiga
antibodi
antiigg
igm
renegar
small
intraven
passiv
transfer
iga
result
iga
nasal
secret
protect
mice
intranas
challeng
influenza
renegar
small
passiv
transfer
nasal
iga
titer
confer
protect
concentr
equival
seen
convalesc
mice
wherea
igg
transud
urt
could
detect
time
normal
convalesc
serum
titer
passiv
transfer
renegar
et
al
moreov
recombin
iga
suffici
prevent
influenza
transmiss
guinea
pig
model
seibert
et
al
human
iga
present
monomer
dimer
form
transcytosi
mucos
epitheli
cell
extra
polypeptid
secretori
compon
ad
dimer
iga
result
molecul
known
secretori
iga
siga
dimer
siga
time
effici
monomer
iga
neutral
influenza
virus
renegar
et
al
dimer
siga
repres
two
subclass
coval
noncoval
join
dimer
respect
subclass
detect
nasal
secret
influenza
infect
howev
ha
preferenti
stimul
respons
brown
et
al
siga
consid
inflammatori
fc
region
avail
activ
immun
cell
bind
complement
siga
also
resist
proteolysi
neutral
virus
insid
epitheli
cell
transport
virus
pass
epitheli
barrier
lamina
propria
back
lumen
sato
kiyono
siga
may
therefor
use
prevent
virus
breach
mucos
barrier
avoid
immunopatholog
activ
inflammatori
respons
directli
limit
number
antigenantibodi
complex
lamina
propria
trigger
inflamm
current
thought
plasma
igg
serv
backup
siga
urt
wherea
lrt
igg
domin
antibodi
involv
protect
renegar
et
al
fc
receptor
igg
mediat
transport
igg
across
epitheli
barrier
transcytosi
permit
transud
igg
serum
lung
abl
neutral
virus
spiekermann
et
al
explain
passiv
transfer
igg
effect
prevent
sever
diseas
respiratori
infect
experiment
anim
serum
igg
antibodi
main
correl
protect
parent
administ
inactiv
influenza
vaccin
human
section
respiratori
viru
vaccin
virus
caus
repeat
infect
typic
character
either
failur
induc
robust
immun
signific
antigen
divers
face
protect
immun
respons
influenza
virus
reinfect
host
antigen
site
evolv
drift
avoid
neutral
prior
immun
infect
induc
strong
homosubtyp
neutral
antibodi
respons
healthi
individu
contribut
recoveri
protect
repeat
influenza
viru
infect
homolog
viru
antigen
similar
viru
wrammert
et
al
moreov
natur
infect
lead
longlast
immun
infect
viru
exampl
influenza
subtyp
reemerg
suscept
member
popul
born
time
similar
virus
previous
circul
shortridg
et
al
howev
influenza
virus
undergo
antigen
drift
shift
effect
period
protect
may
last
antigen
variant
emerg
contrast
robust
strainspecif
protect
influenza
viru
infect
primari
infect
rsv
hpiv
hmpv
provid
partial
protect
reinfect
rsv
commonli
reinfect
host
even
though
genet
divers
viru
extrem
healthi
adult
challeng
everi
month
strain
rsv
infect
time
half
becam
symptomat
hall
et
al
studi
reproduc
experiment
human
challeng
infect
devincenzo
et
al
access
modern
immunolog
techniqu
may
provid
insight
mechan
immun
evas
reinfect
limit
upper
respiratori
tract
unless
subject
immunocompromis
reinfect
may
consequ
highli
preval
contagi
viru
effect
evas
local
innat
immun
steep
gradient
transud
antibodi
serum
nasal
epithelium
graham
altern
rsv
infect
may
alter
characterist
adapt
immun
effector
memori
although
rsv
infect
provid
suffici
antigen
stimulu
induc
antibodi
shinoff
et
al
cell
respons
heidema
et
al
durabl
antibodi
poor
handforth
et
al
dakhama
et
al
collarini
et
al
effici
mean
prevent
respiratori
viru
infect
vaccin
howev
among
respiratori
virus
licens
vaccin
avail
influenza
seem
logic
consid
live
attenu
vaccin
deliv
intranas
protect
respiratori
virus
would
induc
mucos
immun
respons
howev
system
immun
respons
protect
suffici
robust
induc
inactiv
influenza
vaccin
administ
im
rout
moreov
achiev
appropri
balanc
suffici
attenu
immunogen
especi
young
infant
must
vaccin
face
matern
antibodi
challeng
section
describ
licens
vaccin
well
vaccin
current
develop
vaccin
remain
primari
strategi
prevent
control
influenza
lambert
fauci
describ
section
immun
respons
respiratori
viru
infect
influenza
infect
cellmedi
immun
system
mucos
neutral
antibodi
produc
wherea
cellmedi
immun
contribut
significantli
clearanc
primari
influenza
viru
infect
amelior
diseas
caus
reinfect
neutral
antibodi
play
import
role
prevent
reinfect
goal
vaccin
prime
immun
respons
limit
viral
replic
upon
subsequ
infect
inactiv
recombin
hemagglutinin
live
attenu
influenza
vaccin
laiv
licens
use
novel
vaccin
vari
stage
develop
section
focus
licens
vaccin
immun
respons
elicit
determin
clinic
trial
data
owe
antigen
drift
circul
virus
discuss
section
virolog
influenza
vaccin
one
season
may
effect
subsequ
season
year
strain
includ
vaccin
next
influenza
season
chosen
vaccin
seed
virus
gener
lambert
fauci
inactiv
vaccin
influenza
seed
virus
reassort
virus
ha
na
gene
segment
deriv
circul
viru
intern
protein
gene
deriv
vaccin
donor
strain
adapt
high
yield
egg
apuerto
kilbourn
licens
laiv
also
contain
ha
na
circul
viru
combin
intern
protein
gene
temperaturesensit
coldadapt
attenu
master
donor
virus
limit
replic
vaccin
virus
cooler
upper
respiratori
tract
maassab
yield
vaccin
viru
egg
poor
may
eggadapt
serial
passag
vaccin
virus
amplifi
hundr
million
egg
purifi
inactiv
vaccin
virus
treat
formalin
split
deterg
formul
clinic
use
without
thimeros
preserv
fior
et
al
season
influenza
vaccin
trival
contain
two
subtyp
influenza
virus
one
influenza
b
viru
howev
winter
season
northern
hemispher
quadrival
vaccin
contain
two
subtyp
influenza
virus
two
strain
influenza
b
virus
becom
avail
take
sever
month
gener
seed
viru
manufactur
distribut
vaccin
typic
season
influenza
northern
hemispher
manufactur
amplifi
vaccin
virus
inactiv
purifi
februari
late
summer
formul
distribut
administr
fall
anticip
peak
influenza
season
lambert
fauci
pandem
viru
emerg
april
manufactur
season
trival
vaccin
alreadi
way
monoval
vaccin
produc
quickli
possibl
addit
season
vaccin
monoval
vaccin
avail
widespread
use
pandem
peak
northern
hemispher
avail
winter
season
southern
hemispher
broadbent
subbarao
skowronski
et
al
addit
current
global
vaccin
product
capac
cover
highrisk
popul
around
world
girard
et
al
one
mean
increas
capac
move
toward
use
cell
cultur
instead
egg
vaccin
product
sever
compani
investig
addit
amount
ha
vaccin
dose
could
reduc
use
adjuv
howev
adjuv
season
influenza
vaccin
yet
licens
unit
state
trival
inactiv
vaccin
tiv
season
influenza
administ
im
efficaci
rang
prevent
influenza
morbid
mortal
healthi
adolesc
adult
osterholm
et
al
trival
laiv
consist
b
ann
arbor
coldadapt
backbon
togeth
ha
na
target
virus
flumist
medimmun
administ
nasal
spray
licens
sever
countri
includ
north
america
europ
unit
state
season
laiv
licens
healthi
individu
year
age
current
approv
use
children
year
age
approv
use
elderli
immunocompromis
individu
ambros
et
al
substanti
bodi
evid
largescal
random
clinic
trial
demonstr
effect
laiv
number
clinic
studi
also
shown
efficaci
laiv
equival
superior
induc
im
vaccin
tiv
children
review
luke
et
al
adult
howev
major
doubleblind
random
placebocontrol
trial
shown
tiv
greater
efficaci
laiv
monto
et
al
ohmit
et
al
ohmit
et
al
militari
vaccin
effect
also
found
higher
tiv
laiv
except
new
recruit
eickcost
et
al
wang
et
al
tiv
primarili
induc
serum
antibodi
influenza
ha
glycoprotein
typic
measur
hemagglutinin
inhibit
hi
assay
serv
surrog
virusneutr
assay
healthi
individu
immunolog
prime
previou
infect
vaccin
influenzaspecif
antibodysecret
cell
peripher
blood
peak
week
vaccin
serum
antibodi
level
peak
week
postvaccin
howev
unprim
individu
exampl
children
may
take
week
longer
serum
antibodi
level
peak
vaccin
brokstad
et
al
cox
et
al
elmadhun
et
al
rise
serum
antibodi
titer
tiv
administr
document
multipl
isotyp
includ
igm
iga
igg
pronounc
rise
igg
titer
moldoveanu
et
al
contrast
vaccin
laiv
lead
seroconvers
frequent
immunolog
individu
immunolog
prime
exampl
children
singl
dose
trival
laiv
seroconvers
rate
report
influenza
b
respect
increas
second
dose
day
respect
belsh
et
al
lee
et
al
howev
healthi
adult
serum
antibodi
titer
lower
laiv
tiv
vaccin
moldoveanu
et
al
one
studi
laiv
recipi
increas
serum
igg
titer
compar
tiv
recipi
protect
mediat
inactiv
vaccin
therefor
correl
serum
neutral
antibodi
titer
wherea
immun
mechan
contribut
protect
mediat
laiv
higher
percentag
laiv
recipi
mucos
antibodi
antibodysecret
cell
receiv
tiv
one
studi
record
laiv
recipi
increas
influenzaspecif
iga
mucosa
compar
tiv
recipi
moreov
level
iga
nasal
wash
specimen
correl
protect
challeng
wildtyp
influenza
virus
mucos
iga
adult
vaccin
laiv
declin
month
vaccin
addit
iga
igg
also
found
nasal
secret
laiv
moldoveanu
et
al
describ
section
immun
respons
respiratori
viru
infect
iga
major
mediat
immun
influenza
infect
urt
igg
serv
backup
also
appear
case
vaccin
laiv
major
antibodi
induc
influenza
vaccin
associ
protect
direct
globular
head
ha
recent
neutral
antibodi
also
identifi
bind
conserv
epitop
ha
stem
ha
stem
antibodi
found
broadli
neutral
much
effort
gener
vaccin
elicit
antibodi
produc
broadli
crossprotect
vaccin
corti
et
al
ekiert
et
al
kashyap
et
al
okuno
et
al
sui
et
al
addit
antibodi
direct
na
protein
also
gener
vaccin
tiv
laiv
murphi
et
al
antina
antibodi
restrict
viru
releas
infect
cell
reduc
sever
diseas
limit
spread
murphi
et
al
howev
current
licens
inactiv
vaccin
standard
ha
na
protein
content
amount
na
protein
vari
vaccin
vaccin
contribut
vaccineinduc
antina
antibodi
protect
influenza
well
understood
hassantoufighi
et
al
addit
humor
immun
influenzaspecif
cytotox
lymphocyt
ctl
associ
acceler
clearanc
viru
recoveri
infect
howev
extent
cellular
immun
respons
protect
infect
unknown
recal
respons
like
occur
peak
viral
replic
subbarao
et
al
cellmedi
immun
induc
vaccin
less
well
studi
humor
respons
result
variabl
studi
shown
immun
healthi
adult
wholeviru
inactiv
vaccin
result
enhanc
ctl
respons
peripher
blood
wherea
immun
subunit
vaccin
result
poor
ctl
respons
durat
vari
sever
month
year
enni
et
al
mcmichael
et
al
power
belsh
addit
increas
cell
seen
children
age
month
year
age
vaccin
inactiv
vaccin
howev
similar
respons
induc
adult
et
al
cell
also
detect
singl
dose
inactiv
vaccin
amplifi
second
dose
vaccin
mori
et
al
addit
numer
studi
found
signific
increas
cell
vaccin
laiv
adult
children
basha
et
al
forrest
et
al
et
al
hoft
et
al
lanthier
et
al
howev
role
cellular
immun
respons
laivmedi
protect
need
investig
annual
influenzarel
death
unit
state
occur
individu
year
age
older
thompson
et
al
vaccin
elderli
individu
therefor
public
health
prioriti
howev
random
placebocontrol
trial
estim
efficaci
tiv
prevent
influenza
older
adult
govaert
et
al
elderli
individu
often
significantli
reduc
antibodi
respons
influenza
vaccin
goodwin
et
al
quantit
review
elderli
subject
seroconvert
influenza
b
vaccin
respect
compar
younger
subject
goodwin
et
al
impair
abil
elderli
mount
adequ
immun
respons
influenza
vaccin
attribut
immunosenesc
immunosenesc
declin
bodi
abil
fight
infect
mount
novel
immun
respons
recal
respons
targonski
et
al
innat
adapt
respons
implic
impair
function
costimulatori
molecul
alter
secret
inflammatori
cytokin
diminish
function
natur
killer
cell
macrophag
neutrophil
observ
elderli
well
decreas
prolif
capac
b
cell
impair
cell
memori
recal
sullivan
et
al
addit
thymic
involut
declin
cell
output
featur
advanc
age
togeth
lifetim
exposur
varieti
pathogen
lead
reduct
cell
pool
rel
increas
proport
memori
cell
elderli
compar
young
adult
pronounc
function
chang
cell
subset
progress
exhaust
occur
pawelec
et
al
wherea
cell
subset
less
affect
replic
senesc
czesnikiewiczguzik
et
al
tiv
standard
basi
amount
ha
protein
one
dose
per
strain
recommend
healthi
previous
prime
individu
increas
dose
increas
serum
antibodi
respons
vaccin
attempt
enhanc
immun
respons
influenza
vaccin
elderli
highdos
tiv
ha
protein
per
strain
licens
use
person
age
year
older
postlicensur
studi
shown
enhanc
immun
respons
age
group
compar
standard
dose
sullivan
et
al
vaccin
effect
studi
way
addit
tiv
discuss
contain
ha
protein
per
strain
show
higher
efficaci
nonadjuv
tiv
phase
random
clinic
trial
elderli
differ
statist
signific
mcelhaney
et
al
laiv
licens
use
elderli
present
howev
evalu
clinic
studi
person
year
age
older
safe
well
toler
clinic
trial
laiv
administ
addit
tiv
coadministr
report
enhanc
local
haspecif
iga
antibodi
respons
howev
efficaci
combin
greater
tiv
alon
gors
et
al
power
et
al
power
et
al
treanor
et
al
individu
chronic
immunocompromis
condit
serolog
respons
tiv
vaccin
typic
lower
healthi
adult
antibodi
respons
influenza
adequ
hivseroposit
individu
minim
immunodefici
respond
well
antiretrovir
therapi
chadwick
et
al
huang
et
al
madhi
et
al
stapran
et
al
howev
individu
advanc
hiv
diseas
low
cell
count
tiv
may
induc
protect
titer
even
two
dose
kroon
et
al
miotti
et
al
laiv
licens
use
immunocompromis
individu
although
larg
amount
data
avail
immun
respons
season
influenza
vaccin
human
improv
season
pandem
influenza
vaccin
evalu
first
anim
model
commonli
use
model
mice
ferret
mice
immun
inactiv
influenza
vaccin
develop
serum
hi
neutral
antibodi
titer
correl
protect
subsequ
challeng
luke
subbarao
although
cellular
immun
respons
mount
secondari
influenza
infect
woodland
et
al
passiv
transfer
antibodi
protect
immunosuppress
mice
suggest
cellmedi
immun
essenti
protect
suffici
antibodi
present
virelizi
goal
parenter
immun
inactiv
influenza
vaccin
induc
suffici
serum
antibodi
titer
limit
influenza
diseas
protect
mediat
serum
igg
transud
lower
respiratori
tract
neutral
viru
passiv
transfer
immun
serum
mice
reduc
replic
influenza
viru
lung
protect
recipi
mice
lethal
influenza
pneumon
prevent
tracheiti
replic
influenza
viru
urt
ramphal
et
al
natur
influenza
infect
urt
mucos
immun
respons
includ
secretori
iga
antibodi
play
import
role
control
diseas
section
immun
respons
respiratori
viru
infect
sever
studi
document
higher
level
serum
antibodi
requir
provid
protect
respiratori
virus
urt
compar
lrt
princ
et
al
ramphal
et
al
takiguchi
et
al
addit
influenza
ferret
primarili
urt
infect
vaccin
kill
inactiv
influenza
virus
protect
influenza
infect
unless
administ
adjuv
potter
et
al
b
adjuv
probabl
requir
parenter
administ
inactiv
vaccin
elicit
higher
level
serum
igg
antibodi
need
restrict
viral
replic
urt
absenc
robust
mucos
immun
respons
mice
laiv
induc
rang
system
pulmonari
immun
effector
protect
anim
challeng
viru
replic
chen
et
al
lau
et
al
magnitud
pulmonari
iga
memori
lymphocyt
respons
depend
replic
effici
vaccin
viru
respiratori
tract
system
immun
serum
antibodi
titer
memori
lymphocyt
spleen
one
dose
laiv
replic
lung
mice
induc
local
immun
influenzaspecif
lymphocyt
lung
contribut
clearanc
challeng
viru
lung
wherea
contribut
serum
antibodi
splenic
cell
neglig
two
dose
complet
protect
achiev
associ
matur
antibodi
respons
lau
et
al
taken
togeth
data
suggest
laiv
protect
anim
induc
multipl
arm
immun
respons
includ
mucos
immun
pulmonari
system
antibodi
cellular
immun
respons
manner
similar
natur
infect
howev
inactiv
vaccin
aim
induc
serum
antibodi
alon
although
mimic
natur
infect
antibodi
titer
suffici
high
inactiv
vaccin
protect
diseas
caus
influenza
virus
inactiv
influenza
vaccin
serum
antiha
antibodi
titer
correl
well
resist
influenza
infect
peopl
well
anim
model
lower
antibodi
titer
associ
increas
risk
ill
though
specif
antibodi
titer
guarante
protect
infect
identifi
hi
titer
repres
level
anticip
approxim
person
protect
hobson
et
al
benchmark
form
basi
licens
criteria
inactiv
vaccin
cber
although
sever
paper
refer
seroprotect
insuffici
evid
support
use
term
vaccin
benchmark
hi
titer
defin
healthi
adult
experiment
challeng
influenza
viru
hobson
et
al
howev
antibodi
titer
correl
protect
healthi
adult
may
translat
clinic
improv
influenza
outcom
elderli
gors
et
al
addit
laiv
effect
despit
induc
variabl
serum
hi
antibodi
titer
therefor
altern
correl
protect
need
iga
cellular
immun
respons
gener
lung
mice
vaccin
laiv
addit
system
antibodi
cellular
respons
extent
differ
arm
immun
respons
contribut
laivinduc
protect
begin
evalu
chen
et
al
lau
et
al
lau
et
al
laivinduc
nasal
wash
igg
iga
correl
protect
viru
replic
human
challeng
studi
either
serum
antibodi
nasal
wash
iga
predictor
protect
belsh
et
al
cellular
immun
respons
also
investig
correl
laivinduc
protect
one
studi
found
correl
cell
measur
elispot
protect
cultureconfirm
influenza
ill
young
children
forrest
et
al
addit
shown
laiv
alter
express
ifnrel
gene
wherea
tiv
indic
innat
immun
respons
play
import
role
protect
mediat
laiv
nakaya
et
al
adjuv
ad
vaccin
formul
enhanc
immun
respons
antigen
vaccin
aluminum
salt
alum
commonli
histor
use
adjuv
worldwid
act
captur
antigen
inject
site
antigen
slowli
process
present
immun
system
socal
depot
effect
caus
mild
cell
damag
inflamm
promot
immun
enhanc
tetsutani
ishii
moreov
alum
particl
enter
host
cell
bind
dna
introduc
cytoplasm
antigenbear
dc
engag
receptor
promot
mhc
class
ii
present
dct
cell
interact
mckee
et
al
oilinwat
adjuv
novarti
glaxosmithklin
effect
induc
hightit
antigenspecif
serum
antibodi
respons
alum
use
inactiv
splitvirion
influenza
vaccin
europ
adjuv
induc
broad
crossclad
humor
respons
permit
dose
spare
compar
immun
respons
induc
reduc
amount
ha
vaccin
galli
et
al
lerouxroel
et
al
understand
mechan
action
remain
incomplet
neither
appear
act
via
depot
effect
instead
induc
local
transient
proinflammatori
cytokin
chemokin
respons
inject
site
drain
lymph
node
recruit
immun
cell
circul
mice
induc
cytokin
chemokin
peak
local
h
postvaccin
neutrophilmobil
cytokin
lymphocytemobil
cytokin
induc
h
postvaccin
addit
eosinophilrecruit
chemokin
cytokin
induc
low
level
gmcsf
induc
level
margin
background
induc
local
cytokin
respons
parallel
enhanc
recruit
monocyt
granulocyt
drain
lymph
node
morel
et
al
also
induc
local
upregul
cytokin
chemokin
innat
immun
gene
promot
recruit
immun
cell
monocyt
dendrit
cell
granulocyt
howev
mechan
action
found
independ
inflammasom
requir
tlrindepend
signal
pathway
seubert
et
al
wherea
inactiv
vaccin
virus
typic
disrupt
deterg
make
splitvirion
subunit
vaccin
inactiv
whole
influenza
virion
wiv
vaccin
also
develop
virion
left
intact
less
wide
use
increas
reactogen
advers
event
fior
et
al
howev
mice
immun
wiv
vaccin
consist
show
higher
hi
titer
virusneutr
antibodi
titer
subunit
vaccin
well
increas
product
proinflammatori
cytokin
dendrit
cell
plasmacytoid
cell
result
desir
respons
geeraedt
et
al
koyama
et
al
approach
use
inactiv
whole
influenza
vaccin
revisit
pandem
influenza
vaccin
wholevirion
inactiv
vaccin
administ
alum
immunogen
human
kulkarni
et
al
lagler
et
al
lin
et
al
nakayama
et
al
dna
vaccin
encod
one
sever
protein
influenza
virus
induc
immun
respons
target
encod
protein
fynan
et
al
ulmer
et
al
wolff
et
al
dna
vaccin
produc
rapidli
low
cost
howev
design
dna
vaccin
complex
year
shown
numer
factor
play
role
effici
express
promot
gc
content
supercoil
polyadenyl
codon
optim
laddi
weiner
addit
safeti
remain
concern
might
risk
integr
host
genom
klinman
et
al
numer
studi
evalu
dna
vaccin
express
np
ha
protein
anim
model
fu
et
al
saha
et
al
tao
et
al
ulmer
et
al
ulmer
et
al
mice
administr
dna
vaccin
encod
np
protein
influenza
induc
strong
ctl
respons
correl
protect
challeng
homolog
heterolog
virus
ulmer
et
al
addit
one
studi
show
deliv
vaccin
vivo
electropor
instead
classic
epiderm
rout
also
induc
protect
humor
cellular
immun
respons
mice
ferret
nonhuman
primat
laddi
et
al
recent
phase
clinic
trial
adjuv
plasmid
dna
vaccin
encod
influenza
ha
np
elicit
cell
respons
ha
major
subject
np
smith
et
al
licens
influenza
vaccin
primarili
elicit
immun
respons
globular
head
region
ha
glycoprotein
howev
immun
select
pressur
lead
antigen
drift
discuss
section
clinic
featur
epidermolog
new
influenza
vaccin
need
select
season
well
pandem
emerg
remain
difficult
predict
strain
circul
upcom
influenza
season
rate
morbid
mortal
greater
influenza
epidem
viru
vaccin
mismatch
pica
pales
expect
vaccin
capabl
protect
broad
er
spectrum
influenza
virus
would
result
less
frequent
updat
season
influenza
vaccin
would
provid
degre
preexist
immun
novel
strain
emerg
vaccin
aim
provid
broad
crossprotect
multipl
subtyp
influenza
known
univers
vaccin
sever
platform
develop
includ
target
ha
np
na
protein
subbarao
matsuoka
unlik
head
region
ha
stalk
domain
high
degre
sequenc
conserv
influenza
virus
broadli
neutral
stalkreact
antibodi
identifi
antibodi
may
inhibit
phinduc
conform
chang
ha
requir
cellular
entri
prevent
cleavag
discuss
section
virolog
act
via
antibodydepend
cellmedi
cytotox
adcc
activ
complement
howev
ha
stalk
less
immunogen
head
sever
techniqu
employ
elicit
stalkreact
antibodi
includ
remov
head
novel
primeboost
strategi
sequenti
vaccin
chimer
ha
molecul
contain
stalk
region
exot
head
domain
aim
boost
antibodi
conserv
epitop
within
stalk
strategi
test
mice
vari
degre
success
gener
protect
immun
respons
heterolog
influenza
virus
subbarao
matsuoka
taken
togeth
ha
stalkbas
strategi
show
promis
univers
influenza
vaccin
candid
influenza
protein
extend
beyond
viral
envelop
antibodi
extracellular
domain
may
act
via
adcc
nk
cell
activ
complementmedi
lysi
addit
sequenc
conserv
among
human
influenza
virus
make
attract
target
univers
vaccin
howev
peptid
poorli
immunogen
techniqu
improv
immunogen
investig
mice
includ
fuse
peptid
immunogen
carrier
protein
deliv
antigen
viruslik
particl
vlp
review
subbarao
matsuoka
influenza
np
protein
also
conserv
among
influenza
virus
potenti
use
univers
vaccin
expos
surfac
virion
infect
cell
mainli
induc
cellular
immun
respons
phase
clinic
trial
modifi
vaccinia
viru
ankara
mva
express
np
protein
report
reduct
laboratoryconfirm
influenza
infect
experiment
challeng
lilli
et
al
howev
larger
studi
requir
confirm
immun
respons
direct
influenza
na
protein
protect
infect
rather
limit
spread
infect
reduc
sever
diseas
recent
baculovirusexpress
vlp
contain
na
protein
found
induc
heterosubtyp
na
antibodi
mice
protect
homolog
heterolog
challeng
quan
et
al
univers
vaccin
may
therefor
benefit
antina
immun
respons
may
use
combin
sever
compon
univers
vaccin
exampl
np
induc
cellular
respons
ha
induc
humor
respons
howev
sever
challeng
develop
univers
vaccin
outlin
viral
protein
potenti
induc
broad
heterosubtyp
immun
poorli
immunogen
requir
larg
dose
antigen
multipl
dose
addit
adjuv
fusion
immunogen
carrier
use
vector
vlp
addit
regulatori
challeng
includ
determin
defin
potenc
vaccin
need
identifi
immun
correl
protect
develop
valid
assay
measur
addit
clinic
trial
challeng
like
efficaci
measur
term
amelior
diseas
rather
prevent
infect
subbarao
matsuoka
given
hurdl
achiev
truli
univers
vaccin
protect
type
subtyp
influenza
probabl
proceed
stepwis
manner
first
step
vaccin
broadli
crossprotect
current
licens
vaccin
primari
target
popul
rsv
vaccin
young
infant
elderli
hospit
rate
highest
age
group
rsvrelat
death
occur
individu
year
age
thompson
et
al
larg
bodi
evid
protect
infect
confer
mainli
neutral
antibodi
collin
melero
howev
multipl
dose
vaccin
might
necessari
young
infant
immatur
immun
system
presenc
matern
antibodi
addit
protect
immun
mount
infect
protect
subsequ
reinfect
reinfect
common
independ
antigen
chang
viru
collin
melero
factor
present
challeng
rsv
vaccin
yet
vaccin
licens
section
discuss
clinic
trial
data
variou
approach
rsv
vaccin
first
approach
vaccin
develop
formalininactiv
rsv
vaccin
evalu
infant
young
children
concentr
vaccin
given
im
alum
well
toler
moder
immunogen
poorli
protect
infect
fact
vaccine
expos
natur
infect
subsequ
rsv
season
immunemedi
enhanc
diseas
individu
requir
hospit
two
fatal
fulgin
et
al
kapikian
et
al
kim
et
al
subsequ
studi
reveal
vaccineinduc
immun
respons
differ
elicit
natur
infect
poor
induct
neutral
antibodi
murphi
walsh
exagger
tcell
respons
kim
et
al
vaccinemedi
enhanc
diseas
also
occur
murin
model
poor
induct
neutral
antibodi
probabl
due
denatur
antigen
vaccin
lack
antibodi
affin
matur
poor
tlr
stimul
delgado
et
al
addit
exagger
respons
loss
regulatori
cell
contribut
diseas
connor
et
al
connor
et
al
de
swart
et
al
loebbermann
et
al
wari
et
al
therefor
clear
addit
neutral
antibodi
respons
balanc
cell
respons
also
desir
experi
inactiv
rsv
vaccin
consid
unsuit
pediatr
use
altern
approach
sought
seri
live
attenu
vaccin
lav
develop
serial
passag
rsv
suboptim
temperatur
cold
passag
cp
growth
presenc
mutagen
produc
temperaturesensit
ts
mutant
lav
caus
diseas
enhanc
anim
model
clinic
trial
wright
et
al
promis
vaccin
gener
method
well
toler
immunogen
seroneg
infant
children
greater
month
age
caus
mild
congest
younger
infant
deem
insuffici
attenu
wright
et
al
sever
lav
also
develop
use
revers
genet
techniqu
evalu
clinic
trial
promis
strongli
ts
well
toler
infant
first
dose
provid
substanti
reduct
replic
second
dose
vaccin
given
month
later
howev
major
individu
increas
serum
antibodi
titer
indic
immun
mechan
might
play
role
protect
replic
second
dose
vaccin
live
attenu
influenza
vaccin
establish
correl
protect
live
rsv
vaccin
activ
area
research
made
challeng
weak
immun
respons
infant
limit
sampl
write
clinic
trial
way
monitor
toler
immunogen
abil
candid
vaccin
induc
protect
natur
rsv
exposur
commun
collin
melero
genet
chang
employ
gener
candid
lav
includ
delet
code
sequenc
increas
transcript
antigen
synthesi
expens
viral
replic
bermingham
collin
delet
gene
increas
ifn
product
signal
might
limit
viral
replic
patholog
increas
immunogen
teng
et
al
use
attenu
parainfluenza
viru
vector
express
rsv
f
andor
g
protein
also
consid
pediatr
vaccin
hpiv
rsv
piv
advantag
improv
vitro
growth
stabil
compar
rsv
bovin
attenu
human
use
vector
f
hn
gene
human
f
andor
g
protein
rsv
incorpor
make
bival
vaccin
rsv
schmidt
et
al
tang
et
al
one
exampl
approach
clinic
trial
children
older
month
age
seroneg
rsv
collin
melero
vaccin
studi
compris
bovin
vector
human
f
hn
gene
rsv
f
gene
ad
tang
et
al
altern
bovin
murin
sendai
viru
also
evalu
vaccin
backbon
rsv
antigen
insert
jone
et
al
substanti
antigen
crossreact
sendai
viru
viru
may
attenu
human
approach
live
vaccin
rsv
includ
use
alphavirus
elliott
et
al
replicationdefect
adenovirus
shao
et
al
vector
rsv
antigen
addit
rsv
vaccin
infant
also
need
rsv
vaccin
older
children
adult
elderli
howev
individu
like
previous
infect
rsv
preexist
immun
may
restrict
replic
lav
addit
vector
vaccin
approach
base
common
human
pathogen
preexist
immun
vector
may
limit
vaccin
viru
replic
interfer
develop
immun
use
proteinbas
vaccin
popul
current
evalu
diseas
enhanc
document
adult
previous
expos
rsv
candid
rsv
f
proteinbas
vaccin
well
toler
healthi
adult
children
month
age
pregnant
women
elderli
girard
et
al
phase
clinic
trial
involv
children
year
age
cystic
fibrosi
purifi
f
vaccin
induc
fourfold
rise
serum
antibodi
titer
associ
signific
protect
lrti
episod
compar
placebo
anoth
approach
subunit
vaccin
copurifi
f
g
protein
rsva
test
adult
found
induc
neutral
antibodi
vaccine
titer
wane
year
suggest
annual
immun
might
necessari
vaccin
girard
et
al
interestingli
phase
clinic
studi
pregnant
women
vaccin
antif
antibodi
persist
elev
newborn
vaccin
mother
without
enhanc
diseas
matern
immun
could
therefor
strategi
protect
infant
month
age
develop
rsv
vaccin
challeng
durbin
karron
recombin
postfus
form
f
protein
delet
major
hydrophob
region
also
produc
subunit
vaccin
form
stabl
trimer
recogn
neutral
mab
high
level
neutral
antibodi
induc
sera
vaccin
rodent
anim
protect
challeng
may
repres
improv
subunit
vaccin
mclellan
et
al
swanson
et
al
anoth
proteinbas
vaccin
evalu
clinic
trial
consist
fragment
rsv
g
protein
contain
central
conserv
domain
fuse
albuminbind
domain
streptococc
g
protein
express
bacteria
howev
vaccin
immunogen
clinic
trial
associ
hypersensit
reaction
purpura
individu
power
et
al
vlp
also
evalu
use
rsv
vaccin
one
formul
rsvf
particl
vaccin
current
clinic
trial
collin
melero
hope
improv
method
produc
rsv
antigen
use
vlp
result
effect
vaccin
could
given
adult
period
possibl
annual
influenza
vaccin
howev
children
remain
seen
whether
vaccin
develop
suffici
attenu
yet
immunogen
enough
provid
protect
howev
even
complet
protect
unrealist
immun
result
substanti
reduct
viru
replic
may
suffici
prevent
sever
diseas
children
seroposit
hpiv
year
age
hpiv
lrti
major
caus
hospit
age
group
schomack
et
al
young
infant
children
target
popul
hpiv
vaccin
protect
immun
infect
mediat
primarili
mucos
serum
neutral
antibodi
howev
reinfect
common
owe
difficulti
maintain
protect
titer
siga
igg
respiratori
lumen
thu
repres
challeng
vaccin
develop
glezen
et
al
section
review
data
clinic
trial
inactiv
live
vector
hpiv
vaccin
first
approach
taken
hpiv
vaccin
use
formalininactiv
intramuscular
vaccin
although
vaccineinduc
diseas
enhanc
seen
formalininactiv
rsv
observ
evid
protect
either
kim
et
al
subsequ
vaccin
effort
therefor
focus
gener
live
attenu
vaccin
two
approach
investig
use
ts
strain
use
bovin
piv
strain
success
passag
lower
temperatur
shown
attenu
hpiv
promis
vaccin
candid
use
approach
design
number
time
viru
passag
low
temperatur
african
green
monkey
kidney
cell
belsh
hissom
ray
et
al
vaccin
safe
immunogen
adult
seroposit
seroneg
children
infant
month
age
older
belsh
et
al
phase
clinic
trial
children
vaccin
well
toler
previous
seroneg
vaccine
fourfold
greater
rise
serum
geometr
mean
antibodi
titer
belsh
et
al
moreov
coadministr
rsv
piv
vaccin
success
littl
evid
interfer
belsh
et
al
howev
piv
vaccin
overattenu
seroposit
children
adult
bovin
make
attract
lav
known
antigen
relat
human
piv
attenu
human
protect
monkey
challeng
clinic
trial
conduct
adult
seroposit
children
seroneg
infant
children
month
age
residu
matern
antibodi
seroposit
individu
vaccin
overattenu
seroneg
children
infant
vaccin
viru
highli
infecti
despit
replic
vaccin
viru
serum
antibodi
respons
low
consist
incomplet
antigen
related
human
bovin
piv
hn
gene
greenberg
et
al
karron
et
al
phase
clinic
trial
children
show
seroconvers
bovin
occur
vaccin
children
three
dose
seroconvers
occur
vaccine
greenberg
et
al
addit
studi
placebo
group
experienc
infect
highlight
ubiquit
natur
pathogen
studi
conclud
bovin
might
better
serv
backbon
insert
gene
describ
write
one
vaccin
hn
f
gene
rsv
f
gene
insert
bovin
backbon
evalu
clinic
trial
seroneg
children
vaccin
candid
highli
attenu
seroposit
children
adult
addit
vaccin
candid
includ
gener
revers
genet
one
vaccin
contain
mutat
pc
gene
reduc
viru
abil
inhibit
type
ifn
induct
signal
anoth
contain
ts
attenu
mutat
paramyxovirus
sato
wright
age
year
children
infect
hmpv
reinfect
common
hmpv
respons
childhood
hospit
lrti
addit
sever
diseas
also
seen
elderli
immunocompromis
individu
feuillet
et
al
despit
clinic
need
hmpv
vaccin
yet
enter
clinic
trial
data
review
section
studi
anim
model
rsv
vaccin
macaqu
mice
inactiv
hmpv
led
diseas
enhanc
challeng
strong
immun
respons
associ
lack
neutral
antibodi
herfst
et
al
hamelin
et
al
therefor
altern
approach
evalu
includ
solubl
proteinbas
subunit
vaccin
live
attenu
vaccin
dna
vaccin
encod
viral
protein
solubl
fprotein
subunit
vaccin
shown
gener
high
titer
neutral
antibodi
serum
golden
syrian
hamster
cotton
rat
associ
protect
subsequ
infect
cseke
et
al
herfst
et
al
howev
stabl
longterm
immun
induc
monkey
herfst
et
al
live
attenu
vaccin
gener
either
cold
passag
revers
genet
temperaturesensit
virus
confer
complet
protect
heterolog
hmpv
challeng
golden
syrian
hamster
herfst
et
al
recombin
hmpv
lack
region
sh
sh
g
protein
induc
high
titer
neutral
antibodi
protect
hamster
african
green
monkey
piv
hmpv
challeng
biacchesi
et
al
buchholz
et
al
buchholz
et
al
chimer
vaccin
also
develop
subunit
hmpv
fusion
protein
insert
backbon
bovin
piv
also
contain
f
hn
gene
tang
et
al
vaccin
induc
neutral
antibodi
protect
hamster
african
green
monkey
piv
hmpv
challeng
tang
et
al
coronavirus
frequent
caus
respiratori
ill
throughout
world
sarscov
merscov
repres
signific
public
health
threat
howev
present
licens
vaccin
human
coronaviru
infect
though
number
vaccin
licens
anim
coronavirus
sever
vaccin
platform
develop
sarscov
show
great
promis
preclin
studi
whole
sarscov
particl
inactiv
formalin
uv
light
combin
two
techniqu
evalu
mice
ferret
rabbit
nonhuman
primat
vaccin
administ
varieti
rout
test
presenc
absenc
variou
adjuv
gener
vaccin
elicit
serum
igg
respons
anim
model
higher
dose
vaccin
elicit
higher
igg
antibodi
titer
subbarao
moreov
studi
demonstr
inactiv
sarscov
vaccin
efficaci
protect
mice
see
et
al
spruth
et
al
stadler
et
al
nonhuman
primat
qin
et
al
zhou
et
al
although
mani
studi
investig
protect
efficaci
addit
inactiv
sar
vaccin
evalu
clinic
trial
safe
well
toler
induc
neutral
antibodi
lin
et
al
mani
subunit
vaccin
compris
purifi
recombin
sarscov
protein
protein
target
protect
neutral
antibodi
elicit
sarscov
infect
truncat
solubl
form
protein
lack
transmembran
domain
also
neutral
infect
sarscov
bisht
et
al
et
al
zhou
et
al
substanti
reduc
titer
challeng
viru
replic
respiratori
tract
mice
bisht
et
al
trimer
spike
protein
vaccin
trispik
also
immunogen
mice
hamster
provid
protect
challeng
hamster
reduc
occurr
sever
pneumon
evid
pulmonari
consolid
sarscovassoci
hepat
cellular
necrosi
kam
et
al
howev
sera
anim
immun
trispik
associ
increas
viru
entri
human
b
cell
led
concern
antibodydepend
enhanc
diseas
kam
et
al
vector
vaccin
develop
sarscov
approach
sarscov
protein
express
venezuelan
equin
enceph
viru
replicon
particl
vrp
chimer
bovinehuman
vector
recombin
replicationdefect
human
poxviru
mva
attenu
rabi
virus
attenu
vesicular
stomat
viru
subbarao
anim
immun
vector
vaccin
express
protein
sarscov
neutral
antibodi
induc
vaccin
anim
protect
challeng
howev
sarscov
protein
express
anim
protect
challeng
exampl
vrp
express
sarscov
protein
provid
protect
challeng
mice
howev
vrp
express
sarscov
n
protein
vrpn
deme
et
al
moreov
vrpn
vaccin
result
mark
bronchiol
alveol
interstiti
accumul
eosinophil
mononuclear
leukocyt
deme
et
al
addit
chimer
bovin
human
bh
vector
express
sarscov
protein
e
protein
togeth
also
gener
neutral
antibodi
hamster
protect
anim
challeng
wherea
bh
parainfluenza
virus
express
n
e
protein
protect
rout
administr
also
import
determin
protect
efficaci
vaccin
vector
express
sarscov
n
gene
given
im
limit
effect
reduc
pulmonari
replic
challeng
viru
despit
elicit
higher
serum
igg
titer
greater
cellular
immun
vaccin
given
intranas
howev
vaccin
administ
induc
higher
mucos
iga
respons
given
im
provid
protect
pulmonari
replic
suggest
mucos
immun
import
mediat
protect
see
et
al
mice
rabbit
monkey
immun
modifi
vaccinia
viru
mva
vaccin
protect
replic
challeng
viru
bisht
et
al
chen
et
al
howev
ferret
mva
antibodi
declin
rapidli
vaccin
vaccin
protect
anim
replic
spread
challeng
viru
weingartl
et
al
recombin
live
attenu
sarscov
vaccin
viru
express
e
protein
abrog
point
mutat
delet
nucleotid
sequenc
restrict
vitro
attenu
hamster
dediego
et
al
addit
inactiv
exonucleas
attenu
sarscov
result
viru
protect
age
immunocompromis
mous
model
sar
infect
graham
et
al
dna
vaccin
express
sarscov
protein
either
without
cytoplasm
domain
without
cytoplasm
transmembran
domain
also
induc
humor
cellular
immun
mice
protect
anim
replic
challeng
viru
addit
prime
dna
vaccin
boost
inactiv
vaccin
result
increas
cell
stronger
antibodi
respons
zakhartchouk
et
al
dna
vaccin
well
toler
produc
cellular
immun
respons
neutral
antibodi
phase
clinic
trial
martin
et
al
despit
success
preclin
vaccin
develop
sar
outbreak
declar
impetu
sustain
long
enough
mani
product
evalu
clinic
trial
cautionari
note
sarscov
vaccin
associ
varieti
vaccin
platform
pulmonari
immunopatholog
mice
challeng
viru
despit
immunogen
protect
efficaci
tseng
et
al
relev
rodent
model
vaccin
human
remain
uncertain
adenoviru
epidem
describ
adult
especi
militari
recruit
close
crowd
set
lynch
et
al
live
attenu
oral
administ
adenoviru
vaccin
serotyp
caus
respiratori
diseas
use
us
militari
start
top
time
incid
diseas
fell
substanti
howev
manufactur
ceas
vaccin
product
epidem
reemerg
militari
facil
lynch
et
al
new
live
attenu
adenoviru
vaccin
issu
militari
recruit
basic
train
sinc
reduct
rate
febril
respiratori
ill
arm
forc
health
surveil
vaccin
avail
children
civilian
adult
popul
present
though
adenovirus
estim
account
pediatr
adult
respiratori
tract
infect
lynch
et
al
summari
major
studi
evalu
respiratori
viru
vaccin
measur
serum
antibodi
respons
larg
bodi
evid
indic
although
cellular
humor
respons
contribut
clearanc
primari
infect
neutral
antibodi
protect
secondari
infect
humor
respons
readili
detect
vaccin
inactiv
subunit
vaccin
howev
fewer
individu
seroconvert
vaccin
live
vaccin
altern
immun
mechan
mucos
antibodi
respons
probabl
respons
protect
live
attenu
vaccin
immun
correl
protect
investig
respiratori
pathogen
infect
host
mucos
surfac
induct
mucos
immun
vaccin
desir
vaccin
administ
intramuscular
subcutan
inject
induc
protect
immun
system
immun
compart
gener
poor
induc
mucos
immun
respons
mucos
deliv
vaccin
contrast
induc
mucos
system
immun
also
readili
accept
requir
needl
syring
levin
dougan
yuki
kiyono
ongo
research
molecular
cellular
mechan
surfac
immunolog
barrier
system
provid
practic
strategi
develop
new
mucos
vaccin
control
respiratori
virus
cell
locat
follicleassoci
epithelium
malt
play
pivot
role
uptak
lumin
antigen
respiratori
tract
induct
antigenspecif
immun
respons
system
mucos
compart
therefor
logic
attract
develop
mcelltarget
mucos
vaccin
sever
molecul
found
bind
preferenti
cell
ulex
europaeu
specif
fructos
sharma
et
al
rhoprotein
deriv
reoviru
bind
carbohydr
structur
contain
sialic
acid
plasma
membran
cell
heland
et
al
moreov
intranas
vaccin
conjug
either
manocha
et
al
rhoprotein
induc
strong
antigenspecif
plasma
igg
mucos
iga
respons
also
ctl
immun
wu
et
al
addit
novel
mcellspecif
monoclon
antibodi
recent
identifi
select
recogn
cell
goblet
cell
epitheli
cell
use
carrier
mcelltarget
mucos
vaccin
wu
et
al
nochi
et
al
concern
rais
potenti
induct
unwant
mucos
inflamm
associ
cell
target
kuole
chen
addit
research
need
better
understand
cell
sampl
antigen
transcytos
basolater
membran
howev
microparticl
administ
oral
becom
trap
mucu
small
fraction
enter
mucos
induct
site
new
approach
develop
transit
condit
enhanc
number
function
cell
neutra
kozlowski
like
reduc
concern
substanti
interest
exploit
nanoparticl
technolog
drug
vaccin
deliveri
nanoparticl
solid
particl
rang
size
nm
diamet
often
made
biodegrad
materi
antigen
payload
dissolv
entrap
adsorb
attach
encapsul
matrix
particl
releas
particl
degrad
period
time
may
vari
day
week
depend
formul
adair
sever
type
nanoparticl
investig
vaccin
deliveri
proven
safe
nontox
suitabl
load
antigen
includ
polyest
poli
lactic
acid
poli
glycol
acid
copolym
polyorthoest
polyanhydrid
polycarbon
reddi
et
al
materi
protect
antigen
degrad
particl
prepar
chemic
reproduc
manner
within
narrow
size
limit
addit
biopolym
exhibit
natur
adjuv
behavior
exampl
poli
lactid
coglycolid
plga
appear
activ
matur
dc
possibl
provid
necessari
stimulatori
signal
though
exact
mechan
fulli
elucid
bennewitz
babense
yoshida
babense
surfac
modif
nanoparticl
chang
overal
charg
hydrophob
aim
improv
mucoadher
properti
de
rieux
et
al
achiev
coat
stabil
polym
surfact
polyethylen
glycol
use
stabil
properti
enhanc
affin
nanoparticl
mucos
surfac
molecul
lectin
chitosan
also
increas
interact
transport
across
mucos
surfac
interestingli
chitosan
report
abl
open
tight
junction
epitheli
cell
facilit
transport
encapsul
macromolecul
across
epitheli
layer
nanoparticl
coat
mannos
mannan
also
produc
aim
target
mannos
receptor
apc
thu
improv
cell
adhes
uptak
cui
mumper
plgacoat
nanoparticl
vaccin
encapsul
influenza
viru
protein
develop
influenza
ha
protein
retain
antigen
encapsul
mice
vaccin
plga
particl
diamet
mount
system
mucos
respons
protect
intranas
challeng
influenza
viru
amidi
et
al
moldoveanu
et
al
chitosanco
nanoparticl
contain
purifi
influenza
viru
also
test
human
volunt
fourfold
greater
increas
antiha
antibodi
observ
volunt
moreov
singl
dose
intranas
vaccin
result
high
titer
nasal
iga
antibodi
strong
system
antigenspecif
respons
greater
induc
intramuscular
inocul
solubl
influenza
antigen
amidi
et
al
nanoparticleconjug
rsv
protein
also
shown
gener
strong
system
immun
mice
associ
protect
wildtyp
rsv
challeng
kalkanidi
et
al
xiang
et
al
addit
plgacoat
nanoparticl
incorpor
hpiv
hn
f
glycoprotein
shown
induc
virusneutr
antibodi
protect
challeng
infect
hamster
ray
et
al
studi
anim
model
human
shown
choic
adjuv
dramat
affect
immedi
immun
respons
longterm
protect
effect
vaccin
ogra
et
al
galli
et
al
addit
qualiti
immun
respons
especi
develop
highaffin
b
cell
longliv
memori
b
cell
plasma
cell
influenc
choic
adjuv
galli
et
al
although
mechan
yet
fulli
elucid
mucos
adjuv
broadli
classifi
two
categori
act
immunostimulatori
molecul
facilit
vaccin
deliveri
ohagan
former
includ
adjuv
toxinbas
cytokinebas
molecul
associ
innat
immun
exampl
pamp
latter
contain
immunestimul
complex
liposom
live
attenu
vector
chitosan
discuss
mechanist
point
view
mucos
adjuv
modul
innat
immun
respons
way
parenter
administ
vaccin
lambrecht
et
al
tlr
agonist
constitut
major
categori
mucos
adjuv
adjuv
base
pamp
often
formul
oilinwat
emuls
virosom
viruslik
particl
investig
potenti
vaccin
bungen
et
al
close
resembl
nativ
viru
howev
nonrepl
consist
reconstitut
viral
envelop
gener
treatment
deterg
diamet
nm
fall
size
rang
small
particl
virosom
influenza
vaccin
avail
commerci
shown
induc
haspecif
antibodi
im
administr
phase
clinic
trial
reveal
toler
immunogen
matrix
tm
adjuv
virosom
dna
vaccin
cox
et
al
influenza
virosom
incorpor
rsvfusion
protein
also
construct
shown
gener
virusspecif
iga
urt
lrt
administr
adjuv
mice
cusi
et
al
immun
stimul
complex
iscom
nonrepl
particl
nm
diamet
compris
viral
glycoprotein
complex
saponin
deriv
bark
tree
quillaia
saponaria
gregori
et
al
iscom
antigen
number
microorgan
includ
virus
bacteria
parasit
shown
induc
humor
cellmedi
immun
immun
respons
appear
predomin
extens
studi
carri
influenza
viru
iscom
sever
speci
includ
mice
monkey
equin
influenza
iscom
vaccin
avail
commerci
mumford
et
al
influenza
iscom
vaccin
sundquist
et
al
stimul
high
level
virusspecif
igm
igg
serum
antibodi
prolif
cell
respons
macaqu
anim
complet
protect
intratrach
challeng
viru
rimmelzwaan
et
al
intranas
immun
mice
rsv
iscom
induc
high
level
longlast
rsvspecif
iga
urt
lrt
hu
et
al
bovin
rsv
iscom
inocul
subcutan
calv
complet
protect
challeng
virul
bovin
rsv
wherea
calv
immun
convent
bovin
rsv
vaccin
develop
moder
sever
respiratori
diseas
challeng
hagglund
et
al
iscomvaccin
anim
develop
high
titer
nasal
serum
virusspecif
igg
well
serum
iga
correl
protect
detoxifi
deriv
cholera
toxin
ct
heatlabil
enterotoxin
lt
produc
enterotoxigen
escherichia
coli
effect
mucos
adjuv
promot
mucos
system
immun
coadminist
protein
antigen
via
oral
nasal
rout
freytag
clement
mestecki
et
al
result
murin
studi
demonstr
ct
lt
induc
express
andor
apc
deliv
costimulatori
signal
cell
freytag
clement
mestecki
et
al
ct
act
presenc
induc
predominantli
respons
wherea
lt
support
respons
product
recent
vaccin
develop
effort
focus
nasal
administr
antigen
ct
lt
deriv
induct
mucos
iga
byun
et
al
fujihashi
et
al
ct
lt
molecul
consist
one
subunit
five
b
subunit
chimer
molecul
made
spontan
associ
subunit
ct
b
subunit
lt
vice
versa
effect
mucos
adjuv
protein
vaccin
type
helper
respons
induc
dictat
origin
b
subunit
takahashi
et
al
one
exampl
nasal
administr
influenza
ha
subunit
vaccin
togeth
chimer
mutant
ctaltb
adjuv
murin
studi
adjuv
vaccin
protect
anim
influenza
viru
challeng
kweon
et
al
howev
concern
safeti
profil
toxinderiv
adjuv
nasal
administr
mctaltb
target
neuron
tissu
though
affect
traffick
coadminist
vaccin
antigen
neuron
tissu
kweon
et
al
taken
togeth
find
suggest
although
recombin
chimer
toxinbas
molecul
show
promis
new
gener
mucos
adjuv
safeti
ct
adjuv
may
need
improv
inactiv
ltadjuv
intranas
influenza
vaccin
nasalflu
withdrawn
concomit
facial
nerv
paralysi
bell
palsi
note
potenti
advers
event
caus
ct
adjuv
kunzi
et
al
garnerspitz
et
al
sever
cytokin
associ
innat
immun
inflamm
support
gener
antigenspecif
siga
serum
iggiga
may
use
mucos
adjuv
mice
nasal
immun
solubl
antigen
includ
ovalbumin
tetanu
toxoid
tt
plu
develop
antigenspecif
antibodi
respons
similar
induc
coadminist
ct
adjuv
cytokin
promot
antigenspecif
antibodi
respons
initi
follow
minim
antibodi
respons
pattern
associ
predominantli
respons
staat
enni
thompson
staat
furthermor
level
antigenspecif
siga
antibodi
similar
induc
ct
found
mucos
secret
mice
receiv
nasal
result
indic
could
use
mucos
adjuv
apc
known
contribut
creation
appropri
cytokin
environ
growth
develop
respons
two
wellknown
cytokin
secret
apc
influenc
outcom
cell
subsetmedi
immun
respons
vajdi
et
al
rincon
et
al
tt
use
antigen
nasal
coadministr
induc
antigenspecif
serum
igg
antibodi
respons
promot
protect
immun
lethal
challeng
tetanu
toxin
interestingli
wherea
nasal
treatment
promot
mix
respons
support
predominantli
respons
addit
induc
antigenspecif
mucos
iga
antibodi
boyaka
et
al
find
suggest
could
potent
mucos
cytokin
upregul
antigenspecif
mucos
immun
respons
type
ifn
affect
differenti
function
immun
cell
includ
cell
dc
effici
enhanc
primari
antibodi
respons
marrack
et
al
luft
et
al
report
type
ifn
effect
system
mucos
adjuv
promot
immun
respons
proietti
et
al
nasal
administr
influenza
vaccin
type
ifn
effect
induc
serum
antigenspecif
mucos
iga
antibodi
respons
provid
full
protect
influenza
viru
challeng
proietti
et
al
well
known
vaccin
stimul
immun
respons
nalt
effect
induc
mucos
immun
respiratori
tract
brandtzaeg
jabbalgil
intranas
administr
live
attenu
influenza
vaccin
flumist
medimmun
proven
effect
protect
season
influenza
viru
infect
protect
children
drift
influenza
viru
strain
belsh
et
al
mendelman
et
al
furthermor
owe
develop
novel
technolog
aerosol
spray
droplet
deliveri
vaccin
attract
possibl
jabbalgil
addit
rout
vaccin
inocul
sublingu
rout
explor
shim
et
al
czerkinski
et
al
sublingu
epithelium
harbor
dens
lattic
dc
vaccin
deliv
via
rout
stimul
broad
dissemin
mucos
system
immun
respons
similar
intranas
inocul
sublingu
vaccin
solubl
particul
antigen
promot
strong
mucos
iga
system
igg
antibodi
respons
well
cell
respons
overal
sublingu
immun
compar
nasal
immun
magnitud
breadth
anatom
dissemin
induc
immun
respons
importantli
sublingu
administr
redirect
antigen
andor
adjuv
brain
sublingu
vaccin
influenza
shown
protect
mice
lung
infect
song
et
al
addit
sublingu
administr
inactiv
influenza
vaccin
viru
togeth
mucos
adjuv
ct
cuburu
et
al
nontox
mctaltb
adjuv
induc
system
mucos
virusspecif
antibodi
respons
well
ctl
respons
protect
immun
respiratori
challeng
viru
kweon
et
al
song
et
al
studi
demonstr
sublingu
administr
inactiv
influenza
viru
toxin
adjuv
ct
migrat
replic
central
nervou
system
moreov
use
mucos
adjuv
ct
mobil
dc
within
sublingu
epithelium
observ
suggest
sublingu
immun
may
anoth
attract
safe
mucos
rout
administr
respiratori
viru
vaccin
given
global
burden
respiratori
tract
infect
remain
unmet
need
effect
method
intervent
effici
mean
prevent
respiratori
viru
infect
vaccin
howev
among
respiratori
virus
licens
vaccin
avail
influenza
system
immun
respons
protect
absenc
mucos
immun
suffici
robust
induc
im
inactiv
influenza
vaccin
howev
mani
vaccin
develop
respiratori
virus
live
attenu
virus
mucos
administ
although
live
vaccin
show
promis
understand
mechan
protect
mucos
surfac
incomplet
current
lack
adequ
immun
correl
protect
vaccin
addit
immun
respons
mount
natur
infect
often
suffici
prevent
reinfect
may
also
involv
pathogenesi
diseas
achiev
appropri
balanc
suffici
attenu
immunogen
especi
young
infant
must
vaccin
face
immatur
immun
system
matern
antibodi
challeng
